Subjects -> MEDICAL SCIENCES (Total: 8821 journals)
    - ANAESTHESIOLOGY (121 journals)
    - CARDIOVASCULAR DISEASES (350 journals)
    - DENTISTRY (292 journals)
    - ENDOCRINOLOGY (151 journals)
    - FORENSIC SCIENCES (44 journals)
    - HEMATOLOGY (159 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (180 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2458 journals)
    - NURSES AND NURSING (372 journals)
    - OBSTETRICS AND GYNECOLOGY (211 journals)
    - ONCOLOGY (393 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (277 journals)
    - PSYCHIATRY AND NEUROLOGY (848 journals)
    - RESPIRATORY DISEASES (108 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (83 journals)
    - SURGERY (412 journals)

UROLOGY, NEPHROLOGY AND ANDROLOGY (159 journals)                     

Showing 1 - 159 of 159 Journals sorted alphabetically
Acta Urológica Portuguesa     Open Access   (Followers: 1)
Actas Urológicas Españolas     Full-text available via subscription   (Followers: 3)
Actas Urológicas Españolas (English Edition)     Full-text available via subscription   (Followers: 1)
Advances in Chronic Kidney Disease     Full-text available via subscription   (Followers: 11)
Advances in Urology     Open Access   (Followers: 13)
African Journal of Nephrology     Open Access  
African Journal of Urology     Open Access   (Followers: 7)
AJP Renal Physiology     Hybrid Journal   (Followers: 8)
Aktuelle Urologie     Hybrid Journal   (Followers: 4)
American Journal of Kidney Diseases     Hybrid Journal   (Followers: 42)
American Journal of Men's Health     Open Access   (Followers: 9)
American Journal of Nephrology     Full-text available via subscription   (Followers: 38)
Andrologia     Hybrid Journal   (Followers: 2)
Andrology     Hybrid Journal   (Followers: 4)
Andrology & Gynecology : Current Research     Hybrid Journal   (Followers: 4)
Andrology and Genital Surgery     Open Access   (Followers: 7)
Andrology-Open Access     Open Access  
Annales d'Urologie     Full-text available via subscription  
Arab Journal of Nephrology and Transplantation     Open Access   (Followers: 1)
Arab Journal of Urology     Open Access   (Followers: 7)
Archives of Clinical Nephrology     Open Access   (Followers: 2)
Archivio Italiano di Urologia e Andrologia     Open Access   (Followers: 1)
Archivos Españoles de Urología     Open Access  
Asian Journal of Andrology     Open Access   (Followers: 1)
Asian Journal of Urology     Open Access   (Followers: 3)
Bangladesh Journal of Urology     Open Access   (Followers: 5)
BANTAO Journal     Open Access  
Basic and Clinical Andrology     Open Access  
BJU International     Hybrid Journal   (Followers: 34)
BJUI Compass     Open Access   (Followers: 2)
BMC Nephrology     Open Access   (Followers: 11)
BMC Urology     Open Access   (Followers: 14)
Canadian Journal of Kidney Health and Disease     Open Access   (Followers: 8)
Canadian Urological Association Journal     Open Access   (Followers: 2)
Cancer Urology     Open Access   (Followers: 2)
Cardiorenal Medicine     Full-text available via subscription   (Followers: 1)
Case Reports in Nephrology     Open Access   (Followers: 5)
Case Reports in Nephrology and Dialysis     Open Access   (Followers: 9)
Case Reports in Urology     Open Access   (Followers: 12)
Clinical and Experimental Nephrology     Hybrid Journal   (Followers: 4)
Clinical Journal of the American Society of Nephrology     Full-text available via subscription   (Followers: 22)
Clinical Kidney Journal     Open Access   (Followers: 4)
Clinical Medicine Insights : Urology     Open Access   (Followers: 3)
Clinical Nephrology     Full-text available via subscription   (Followers: 8)
Clinical Nephrology and Urology Science     Open Access   (Followers: 6)
Clinical Queries: Nephrology     Hybrid Journal   (Followers: 1)
Cuadernos de Cirugía     Open Access   (Followers: 3)
Current Opinion in Nephrology & Hypertension     Hybrid Journal   (Followers: 10)
Current Opinion in Urology     Hybrid Journal   (Followers: 12)
Current Urology     Open Access   (Followers: 10)
Current Urology Reports     Hybrid Journal   (Followers: 5)
Der Nephrologe     Hybrid Journal  
Der Urologe     Hybrid Journal   (Followers: 1)
Diabetic Nephropathy     Open Access   (Followers: 1)
EMC - Urología     Full-text available via subscription  
Enfermería Nefrológica     Open Access   (Followers: 1)
European Urology     Full-text available via subscription   (Followers: 33)
European Urology Focus     Hybrid Journal   (Followers: 5)
European Urology Oncology     Hybrid Journal   (Followers: 1)
European Urology Open Science     Open Access   (Followers: 10)
Forum Nefrologiczne     Full-text available via subscription  
Geriatric Nephrology and Urology     Hybrid Journal   (Followers: 7)
Giornale di Clinica Nefrologica e Dialisi     Open Access  
Herald Urology     Open Access   (Followers: 2)
Hong Kong Journal of Nephrology     Open Access   (Followers: 3)
Human Andrology     Partially Free   (Followers: 2)
IJU Case Reports     Open Access  
Indian Journal of Nephrology     Open Access   (Followers: 2)
Indian Journal of Urology     Open Access   (Followers: 5)
International Brazilian Journal of Urology     Open Access   (Followers: 5)
International Journal of Nephrology     Open Access   (Followers: 2)
International Journal of Nephrology and Renovascular Disease     Open Access   (Followers: 2)
International Journal of Urology     Hybrid Journal   (Followers: 12)
International Urology and Nephrology     Hybrid Journal   (Followers: 7)
Jornal Brasileiro de Nefrologia     Open Access  
Journal für Urologie und Urogynäkologie/Österreich     Hybrid Journal  
Journal of Clinical Nephrology     Open Access   (Followers: 2)
Journal of Clinical Urology     Hybrid Journal   (Followers: 14)
Journal of Endoluminal Endourology     Open Access  
Journal of Endourology     Hybrid Journal   (Followers: 2)
Journal of Endourology Case Reports     Hybrid Journal  
Journal of Genital System & Disorders     Hybrid Journal   (Followers: 3)
Journal of Integrative Nephrology and Andrology     Open Access   (Followers: 2)
Journal of Kidney Cancer and VHL     Open Access  
Journal of Lower Genital Tract Disease     Hybrid Journal  
Journal of Nephrology     Hybrid Journal   (Followers: 4)
Journal of Nephrology Research     Open Access   (Followers: 3)
Journal of Pediatric Nephrology     Open Access   (Followers: 5)
Journal of Renal Care     Hybrid Journal   (Followers: 8)
Journal of Renal Nursing     Full-text available via subscription   (Followers: 12)
Journal of Renal Nutrition     Hybrid Journal   (Followers: 28)
Journal of Renal Nutrition and Metabolism     Open Access   (Followers: 1)
Journal of the American Society of Nephrology     Full-text available via subscription   (Followers: 31)
Journal of The Egyptian Society of Nephrology and Transplantation     Open Access  
Journal of Translational Neurosciences     Open Access  
Journal of Urology     Full-text available via subscription   (Followers: 46)
Journal of Urology & Nephrology     Open Access   (Followers: 2)
Kidney Disease and Transplantation     Open Access   (Followers: 4)
Kidney Diseases     Open Access   (Followers: 3)
Kidney International     Hybrid Journal   (Followers: 46)
Kidney International Reports     Open Access   (Followers: 3)
Kidney Medicine     Open Access  
Kidney Research Journal     Open Access   (Followers: 6)
Kidneys (Počki)     Open Access   (Followers: 1)
Nature Reviews Nephrology     Full-text available via subscription   (Followers: 22)
Nature Reviews Urology     Full-text available via subscription   (Followers: 13)
Nefrología (English Edition)     Open Access  
Nefrología (Madrid)     Open Access  
Nephro-Urology Monthly     Open Access   (Followers: 1)
Nephrology     Hybrid Journal   (Followers: 13)
Nephrology Dialysis Transplantation     Hybrid Journal   (Followers: 27)
Nephron     Hybrid Journal   (Followers: 4)
Nephron Clinical Practice     Full-text available via subscription   (Followers: 4)
Nephron Experimental Nephrology     Full-text available via subscription   (Followers: 4)
Nephron Extra     Open Access   (Followers: 1)
Nephron Physiology     Full-text available via subscription   (Followers: 4)
Neurourology and Urodynamics     Hybrid Journal   (Followers: 1)
OA Nephrology     Open Access   (Followers: 2)
Open Access Journal of Urology     Open Access   (Followers: 6)
Open Journal of Nephrology     Open Access   (Followers: 5)
Open Journal of Urology     Open Access   (Followers: 6)
Open Urology & Nephrology Journal     Open Access  
Pediatric Urology Case Reports     Open Access   (Followers: 7)
Portuguese Journal of Nephrology & Hypertension     Open Access   (Followers: 1)
Progrès en Urologie     Full-text available via subscription  
Progrès en Urologie - FMC     Full-text available via subscription  
Prostate Cancer and Prostatic Diseases     Hybrid Journal   (Followers: 6)
Renal Failure     Open Access   (Followers: 12)
Renal Replacement Therapy     Open Access   (Followers: 4)
Research and Reports in Urology     Open Access   (Followers: 4)
Revista de Nefrología, Diálisis y Trasplante     Open Access   (Followers: 1)
Revista Mexicana de Urología     Open Access   (Followers: 1)
Revista Urologia Colombiana     Open Access  
Saudi Journal of Kidney Diseases and Transplantation     Open Access   (Followers: 2)
Scandinavian Journal of Urology     Hybrid Journal   (Followers: 7)
Seminars in Nephrology     Hybrid Journal   (Followers: 11)
The Prostate     Hybrid Journal   (Followers: 8)
Therapeutic Advances in Urology     Open Access   (Followers: 4)
Trends in Urology & Men's Health     Partially Free   (Followers: 1)
Ukrainian Journal of Nephrology and Dialysis     Open Access   (Followers: 1)
Uro-News     Hybrid Journal   (Followers: 1)
Urolithiasis     Hybrid Journal   (Followers: 2)
Urologia Internationalis     Full-text available via subscription   (Followers: 2)
Urologia Journal     Hybrid Journal  
Urologic Clinics of North America     Full-text available via subscription   (Followers: 4)
Urologic Nursing     Full-text available via subscription   (Followers: 4)
Urologic Radiology     Hybrid Journal  
Urological Science     Open Access  
Urologicheskie Vedomosti     Open Access  
Urologie in der Praxis     Hybrid Journal  
Urologie Scan     Hybrid Journal  
Urology     Hybrid Journal   (Followers: 33)
Urology Annals     Open Access   (Followers: 4)
Urology Case Reports     Open Access   (Followers: 3)
Urology Practice     Full-text available via subscription   (Followers: 2)
Urology Times     Free   (Followers: 3)
Urology Video Journal     Open Access   (Followers: 1)
World Journal of Nephrology and Urology     Open Access   (Followers: 15)
World Journal of Urology     Hybrid Journal   (Followers: 11)


Similar Journals
Journal Cover
Kidney International
Journal Prestige (SJR): 3.238
Citation Impact (citeScore): 5
Number of Followers: 46  
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 0085-2538 - ISSN (Online) 1523-1755
Published by NPG Homepage  [142 journals]
  • Subscription Information
    • Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/S0085-2538(21)00304-5
      Issue No: Vol. 99, No. 5 (2021)
  • In this issue
    • First page: 1041
      Abstract: Hospitalized patients taking renin-angiotensin aldosterone inhibitors (RAASi) who have an episode of acute kidney injury (AKI) often have these medications discontinued and not restarted after hospital discharge, because of the preconceived notion that continuing RAASi will impair recovery from AKI or predispose to recurrent AKI. Siew and colleagues examined this in a nationwide study of moderate to severe AKI in hospitalized veterans who were restarted or not on RAASi at hospital discharge, or who were initiated on RAASi for the first time at discharge.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.03.003
      Issue No: Vol. 99, No. 5 (2021)
  • In memoriam: Robert W. Schrier, 1936–2021
    • Authors: Tomas Berl; Stuart Linas
      Pages: 1042 - 1044
      Abstract: As the sun was setting on the 23rd day of January, the passing of Dr. Robert W. Schrier marked the loss of one of nephrology’s towering figures. For more than a half of a century, in his uncompromising pursuit of excellence, he was one of the most respected, beloved, and admired physicians in the world. His boundless energy, consistent optimism, focused determination, and unparalleled work ethic brought about transformative changes to the Renal Division and soon thereafter to the entire Department of Medicine at the University of Colorado.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.03.004
      Issue No: Vol. 99, No. 5 (2021)
  • Journal Club
    • Pages: 1054 - 1056
      Abstract: Mueller et al. (JAMA. 2021;325:542–551.)
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.03.001
      Issue No: Vol. 99, No. 5 (2021)
  • Reversing endothelial dysfunction with empagliflozin to improve
           cardiomyocyte function in cardiorenal syndrome
    • Authors: Laetitia Dou; Stéphane Burtey
      Pages: 1062 - 1064
      Abstract: Sodium-glucose cotransporter 2 inhibitors offer cardiovascular and renal benefits in patients with chronic kidney disease through not yet clearly defined mechanisms. Juni et al. showed that sodium-glucose cotransporter 2 inhibitor empagliflozin exposure in vitro can restore cardiomyocyte function by counteracting harmful effects of uremic serum on the endothelium-cardiomyocyte crosstalk between endothelial cells and cardiomyocytes. The author’s findings improved our understanding of cardiovascular impairment in chronic kidney disease and provided new perspectives for the beneficial effects of sodium-glucose cotransporter 2 inhibitor therapy.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.01.008
      Issue No: Vol. 99, No. 5 (2021)
  • My, oh, MYO9A! Just how complex can regulation of the podocyte actin
           cytoskeleton get'
    • Authors: Johannes S. Schlöndorff
      Pages: 1065 - 1067
      Abstract: Genetics contributes significantly to the development of kidney diseases. In the case of glomerular diseases such as focal segmental glomerulosclerosis, over a dozen genes involved in maintaining and regulating the actin cytoskeleton of podocytes have been implicated. A new study adds the atypical myosin, MYO9A, to that list using a combination of human and mouse genetics, suggesting a link to enhanced RhoA activity. Unraveling the growing web of actin regulators remains a key challenge to understanding podocytopathies.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.01.006
      Issue No: Vol. 99, No. 5 (2021)
  • Coagulation anomalies, endothelial dysfunction, and aortic stiffness
    • Authors: Mohsen Agharazii
      Pages: 1067 - 1070
      Abstract: In chronic kidney disease, the arterial wall undergoes complex remodeling, which leads to aortic stiffness. This causes increased cardiac workload and enhanced pulse pressure transmission into microcirculation, leading to microvascular damage and organ dysfunction. Beyond regulation of vascular tone, endothelium plays a key role in coagulation. In hemodialysis patients, Tran et al. show that the ongoing coagulation activity is associated with aortic stiffness. In contrast, anticoagulant factors are increased, explaining reduced endogenous thrombin potential and the increased bleeding risk.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.01.020
      Issue No: Vol. 99, No. 5 (2021)
  • Parathyroid hormone oxidation in chronic kidney disease: clinical
    • Authors: Tilman B. Drüeke; Jürgen Floege
      Pages: 1070 - 1072
      Abstract: In chronic kidney disease, parathyroid hormone (PTH), like all proteins, can undergo post-translational modifications, including oxidation. This can lead to structural and functional changes of the hormone. It has been hypothesized that currently used PTH measurement methods do not adequately reflect PTH-related bone and cardiovascular abnormalities in chronic kidney disease owing to the presence of oxidized, biologically inactive PTH in the circulation. Ursem et al. now report a strong correlation between serum non-oxidized and total PTH, and comparable associations with histomorphometric and circulating bone turnover markers, pleading against this hypothesis.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.01.019
      Issue No: Vol. 99, No. 5 (2021)
  • Medullary tophi: multiple microscopic lesions can amount to significant
           renal damage
    • Authors: Laura C. Malone; John C. Papadimitriou, Cinthia B. Drachenberg
      Pages: 1239 - 1240
      Abstract: We read with great interest the study of Bardin et al., who found an association between long-standing untreated gout and medullary echogenicity, likely due to urate deposition.1 The linked commentary highlights the controversy regarding the pathogenetic role of gout in kidney damage and chronic kidney disease (CKD).2 The role of asymptomatic hyperuricemia remains unclear, but a recent study suggests that hyperuricemia with crystal deposition determines progression to CKD.3 A retrospective evaluation of 796 native kidney biopsies with abundant medulla identified tophi in only 4.5%, but this finding was strongly associated with CKD.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.02.007
      Issue No: Vol. 99, No. 5 (2021)
  • Biomarkers for early detection of kidney disease: a call for
           pathophysiological relevance
    • Authors: Justyna Siwy; Harald Mischak, Joachim Beige, Peter Rossing, Bernd Stegmayr
      Pages: 1240 - 1241
      Abstract: In the January 2021 issue of Kidney International, Shlipak et al. published conclusions of “Early Identification and Intervention in CKD” conference held by Kidney Disease: Improving Global Outcomes (KDIGO).1 The authors highlight the importance of early identification and intervention for chronic kidney disease (CKD) in patient management and propose CKD screening by assessing dual evaluation of estimated glomerular filtration rate and albuminuria (urine albumin-to-creatinine ratio). However, besides limited accuracy, especially in early CKD, these biomarkers are the consequence of disease and are not connected to molecular pathophysiology.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.02.008
      Issue No: Vol. 99, No. 5 (2021)
  • An impending obituary for the primacy of P values in glomerulonephritis
           trial results'
    • Authors: Carl P. Walther
      Pages: 1241 - 1242
      Abstract: Anders et al. provide a valuable service in presenting an outstanding and succinct synopsis of the recent sea change in lupus nephritis therapeutic options driven by 3 recent trials, and eulogize the concept of induction and maintenance therapy.1 Their eulogy makes a convincing case that dichotomizing lupus nephritis therapy into induction or maintenance phases is not only obsolete and inaccurate, but has also hindered progress. They then provide perfectly bite-sized summaries of 3 recent trials—invaluable for clinicians, clinical scientists, and trainees—summaries that are perfect until results are discussed, where the primacy of the P value rears its ugly head.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.02.010
      Issue No: Vol. 99, No. 5 (2021)
  • The authors reply
    • Authors: Sri Lekha Tummalapalli; Michael G. Shlipak, Michael Cheung, Sophia Zoungas
      First page: 1241
      Abstract: We thank Siwy and colleagues for their response1 to our conference report on “Early Identification and Intervention in Chronic Kidney Disease (CKD),” held by Kidney Disease: Improving Global Outcomes (KDIGO).2 Accurate, unbiased, and precise biomarkers are the foundation for early detection and risk stratification of CKD. We agree that there is great opportunity for novel biomarkers to better capture the pathophysiology of glomerular and tubular injury and improve our predictions of cardiovascular and kidney outcomes.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.02.009
      Issue No: Vol. 99, No. 5 (2021)
  • STARMEN: progress in membranous nephropathy'
    • Authors: Fiona A. Chapman; Neeraj Dhaun
      Pages: 1242 - 1243
      Abstract: The Sequential Treatment with Tacrolimus and Rituximab Versus Alternating Corticosteroids and Cyclophosphamide in PMN (STARMEN) trialists demonstrate the superiority of a corticosteroid-cyclophosphamide regimen over tacrolimus-rituximab.1 However, we suggest cautious extrapolation of these findings to the clinic. In this study, patients had modest nephrotic syndrome (serum albumin, 2.6 g/L; proteinuria, 7.4 g/24 h) with preserved estimated glomerular filtration rate (∼80 ml/min), representing a population at low risk of disease progression.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.01.025
      Issue No: Vol. 99, No. 5 (2021)
  • The authors reply
    • Authors: Hans-Joachim Anders; Yutian Lei, Brad H. Rovin
      First page: 1242
      Abstract: We echo that number needed to treat and benefit per hundred with confidence intervals extracts more intuitive information for clinician and patients.1 Another nail in the P value coffin is the significant P value but a biologically irrelevant effect size, in large studies, but these 3 new drugs reached clinically relevant results.2 They did especially in view of the many previous “negative trials” for lupus nephritis that did not reach the prespecified P value and number needed to treat, with confidence intervals reaching the negative range.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.02.011
      Issue No: Vol. 99, No. 5 (2021)
  • The authors reply
    • Authors: Gema Fernández-Juárez; Jorge Rojas-Rivera, Manuel Praga
      First page: 1243
      Abstract: We thank Chapman and Dhaun for their comments.1 We agree about the need of a personalized treatment of membranous nephropathy, but we think that the Sequential Treatment with Tacrolimus and Rituximab Versus Alternating Corticosteroids and Cyclophosphamide in PMN (STARMEN) trial2 provides interesting data for this purpose. Our results confirm the efficacy of cyclic alternating treatment with corticosteroids and cyclophosphamide (84% of remissions at 24 months, most of them complete). Although the classic 6-month alternating scheme is not tolerated by some patients, its rapidity in inducing immunologic and clinical remission (77% and 51%, respectively, at 3 months) should be emphasized, which opens the possibility of shorter and more flexible combinations of corticosteroids and cyclophosphamide.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.02.013
      Issue No: Vol. 99, No. 5 (2021)
  • Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S,
           Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D
           and Haller H; on behalf of the 311 Study Group. The long-acting C5
           inhibitor, Ravulizumab, is effective and safe in adult patients with
           atypical hemolytic uremic syndrome naïve to complement inhibitor
           treatment.” Kidney Int. 2020;97:1287–1296
    • Authors: Eric Rondeau; Marie Scully, Gema Ariceta, Tom Barbour, Spero Cataland, Nils Heyne, Yoshitaka Miyakawa, Stephan Ortiz, Eugene Swenson, Marc Vallee, Sung-Soo Yoon, David Kavanagh, Hermann Haller, 311 Study Group
      First page: 1244
      Abstract: The authors regret that 2 investigators were not included in the 311 Study Group. Members of the 311 Study Group are listed in the Appendix.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2021.03.008
      Issue No: Vol. 99, No. 5 (2021)
  • Epstein-Barr virus–associated hepatic smooth muscle tumor
           post–renal transplant
    • Authors: Balamurugan Thirunavukkarasu; Ritambhra Nada, Raja Ramachandran, Vinay Sakhuja
      First page: 1245
      Abstract: A 48-year-old gentleman, post–live related renal transplant presented 2.5 years after transplantation with epigastric pain of 3 months in duration. His native kidney disease was diabetic nephropathy. The patient was on tacrolimus, azathioprine, and prednisolone without episode of rejection. Abdominal computed tomography scan revealed multiple hypodense focal lesions of varying sizes in the lobes of both the liver and spleen (Figure 1). A clinical diagnosis of posttransplant lymphoproliferative disorder was made.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2020.09.001
      Issue No: Vol. 99, No. 5 (2021)
  • The origin of urinary mulberry cells in Fabry disease
    • Authors: Takashi Yokoyama; Shun Manabe, Shigeru Horita, Hiroshi Kataoka, Toshio Mochizuki, Kosaku Nitta
      First page: 1246
      Abstract: Fabry disease is an X-linked lysosomal storage disorder in which α-galactosidase A deficiency leads to cellular accumulation of glycolipids, such as globotriaosylceramide, and nephropathy. Mulberry cells are exfoliated, and vacuolated epithelial cells that resemble a mulberry filled with mulberry bodies, which are whirl-shaped fat globules (insets in Figures 1 and 2). Mulberry cells are frequently detected in patient urine sediment, but their origin remains unclear. Herein, clinical specimens from a Fabry disease case (69-year-old Japanese woman) who was diagnosed based on family history and renal biopsy findings were investigated to determine the mulberry cell origin.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2020.08.019
      Issue No: Vol. 99, No. 5 (2021)
  • The Case Severe hyponatremia in a young cyclist
    • Authors: Romain Muller; Manon Laforet, Mourad Hallah, Clemence Lombardin, Dominique Jaubert, Gaetan Lebrun
      Pages: 1247 - 1248
      Abstract: A 25-year-old woman presented to the emergency department of the Aix-Pertuis Inter-communal Hospital (CHIAP) referred by her general practitioner because of severe hyponatremia at 114 mmol/l. This biological assessment was carried out as part of the etiological assessment of headaches and asthenia that appeared progressively over the previous few days. The patient was not taking any treatment and had no history apart from a head trauma after a bicycle accident 8 days before. The patient was wearing a helmet at the time of the accident and had no alteration of consciousness, anterograde amnesia, or vomiting in the aftermath.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2020.12.004
      Issue No: Vol. 99, No. 5 (2021)
  • The Case Proteinuria in a patient with hematopoietic stem cell
    • Authors: Marco Bonilla; Vanesa Bijol, Rimda Wanchoo, Alla Keyzner, Kenar D. Jhaveri
      Pages: 1249 - 1250
      Abstract: A 61-year-old White female with a history of endometriosis was referred for new-onset nephrotic-range proteinuria. The patient was diagnosed with JAK2 V617F-positive primary myelofibrosis in 2010. For treatment, she was started on various JAK inhibitors as single agents or in combination with nonselective histone deacetylase inhibitor (itacitinib, panobinostat, and ruxolitinib) in 2017, followed by reduced-intensity peripheral blood stem cell transplantation (SCT) from a matched, unrelated male donor.
      Citation: Kidney International 99, 5 (2021)
      PubDate: 2021-05
      DOI: 10.1016/j.kint.2020.12.005
      Issue No: Vol. 99, No. 5 (2021)
  • Minimal Change Disease relapse following SARS-CoV2 mRNA vaccine
    • Authors: Delphine Kervella; Lola Jacquemont, Agnès Chapelet-debout, M.D. Clément deltombe, Simon Ville
      Abstract: Although the pathogenesis of minimal change disease (MCD) has not yet been clearly elucidated, immune dysregulation is probable1 and the risk of relapse after administration of various vaccines (especially meningococcal C conjugate vaccines) has been suggested2,3. Here, we report a case of MCD relapse following SARS-CoV2 mRNA vaccine.
      Citation: Kidney International (2021)
      PubDate: 2021-05-05
      DOI: 10.1016/j.kint.2021.04.033
  • Development of an international Delphi survey to establish core outcome
           domains for trials in adults with glomerular disease.
    • Authors: Simon A. Carter; Charlotte Logeman, Martin Howell, Dan Cattran, Liz Lightstone, Arvind Bagga, Sean J. Barbour, Jonathan Barratt, John Boletis, Dawn J. Caster, Rosanna Coppo, Fernando C. Fervenza, Jürgen Floege, Michelle A. Hladunewich, Jonathan J. Hogan, A. Richard Kitching, Richard A. Lafayette, Ana Malvar, Jai Radhakrishnan, Brad H. Rovin, Nicole Scholes-Robertson, Hérnan Trimarchi, Hong Zhang, Yeoungjee Cho, Louese Dunn, Debbie S. Gipson, Adrian Liew, Benedicte Sautenet, Andrea K. Viecelli, David Harris, David W. Johnson, Angela Yee-Moon Wang, Armando Teixeira-Pinto, Stephen I. Alexander, Adam Martin GradCert, Allison Tong, Jonathan C. Craig
      Abstract: Outcomes relevant to treatment decision-making are inconsistently reported in trials involving glomerular disease. Here, we sought to establish a consensus-derived set of critically important outcomes designed to be reported in all future trials by using an online, international two-round Delphi survey in English. To develop this, patients with glomerular disease, caregivers and health professionals aged 18 years and older rated the importance of outcomes using a Likert scale and a Best-Worst scale.
      Citation: Kidney International (2021)
      PubDate: 2021-05-05
      DOI: 10.1016/j.kint.2021.04.027
  • Central and Peripheral Arterial Diseases in Chronic Kidney Disease:
           Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO)
           Controversies Conference
    • Authors: Kirsten L. Johansen; Pranav S. Garimella, Caitlin W. Hicks, Philip A. Kalra, Dearbhla M. Kelly, Sven Martens, Kunihiro Matsushita, Pantelis Sarafidis, Manish M. Sood, Charles A. Herzog, Michael Cheung, Michel Jadoul, Wolfgang C. Winkelmayer, Holger Reinecke, Conference Participants
      Abstract: Chronic kidney disease (CKD) affects about 10% of all populations worldwide, with about 2 million people requiring dialysis. Although patients with CKD are at high risk of cardiovascular disease (CVD) and events, they are often underrepresented or excluded in clinical trials, leading to important knowledge gaps about how to treat these patients. KDIGO (Kidney Disease: Improving Global Outcomes) convened the fourth Clinical Controversies Conference on the Heart, Kidney and Vasculature in Dublin, Ireland, in February 2020, entitled “Central and Peripheral Arterial Diseases in Chronic Kidney Disease.” A global panel of multidisciplinary experts from the fields of nephrology, cardiology, neurology, surgery, radiology, vascular biology, epidemiology and health economics attended.
      Citation: Kidney International (2021)
      PubDate: 2021-05-04
      DOI: 10.1016/j.kint.2021.04.029
  • Jurisdictional inequalities in deceased donor kidney allocation in
    • Authors: Anne Hu; Cameron Stewart, Jonathan C. Craig, Kate Wyburn, Henry Pleass, John Kanellis, Wai H. Lim, Jean Yang, Germaine Wong
      Abstract: Transplant recipients generally live longer and have better overall quality of life compared to patients treated with maintenance dialysis1. However, not all patients on dialysis waiting for a kidney transplant will enjoy the benefits of transplantation before death. The annual mortality rate on the Australian deceased donor kidney transplant waiting list is approximately 2-5% (varied by age of the transplant candidates), owing largely to cardiovascular-related deaths. The major impediment to transplantation is shortage of donor organs.
      Citation: Kidney International (2021)
      PubDate: 2021-05-04
      DOI: 10.1016/j.kint.2021.04.028
  • Nasal-associated lymphoid tissue is the major induction site for
           nephritogenic IgA in murine IgA nephropathy
    • Authors: Toshiki Kano; Hitoshi Suzuki, Yuko Makita, Yusuke Fukao, Yusuke Suzuki
      Abstract: Dysregulation of mucosal immunity may play a role in the pathogenesis of IgA nephropathy (IgAN). However, it is unclear whether the nasal-associated lymphoid tissue (NALT) or gut-associated lymphatic tissue is the major induction site of nephritogenic IgA synthesis.To examine whether exogenous mucosal antigens exacerbate the pathogenesis of IgAN, we assessed the disease phenotypes of IgAN-onset ddY mice housed germ-free. These mice were transferred to a specific pathogen-free environment and divided into three groups: challenged with the Toll-like receptor 9 (TLR9) ligand CpG-oligodeoxynucleotide, fecal transplantation, and the untreated control group.
      Citation: Kidney International (2021)
      PubDate: 2021-05-04
      DOI: 10.1016/j.kint.2021.04.026
  • Across scales: Novel insights into kidney health and disease by structural
    • Authors: Nicola M. Tomas; Simon A. Mortensen, Matthias Wilmanns, Tobias B. Huber
      Abstract: Over the last decades, structural biology methods such as X-ray crystallography and cryo-electron microscopy have been increasingly used to study protein functions, molecular interactions, physiological processes, and disease mechanisms. This review will outline a selection of structural biology methods, highlight recent examples of how structural analyses have contributed to a more profound understanding of the machinery of life, and give a perspective on how these methods can be applied to investigate functions of kidney molecules and pathogenic mechanisms of renal diseases.
      Citation: Kidney International (2021)
      PubDate: 2021-04-30
      DOI: 10.1016/j.kint.2021.03.042
  • Activation of the kidney sodium chloride cotransporter by the
           β2-adrenergic receptor agonist salbutamol increases blood pressure.
    • Authors: Søren B. Poulsen; Lei Cheng, David Penton, Marleen L.A. Kortenoeven, Vladimir V. Matchkov, Johannes Loffing, Robert Little, Sathish K. Murali, Robert A. Fenton
      Abstract: The thiazide-sensitive sodium-chloride-cotransporter (NCC) in the kidney distal convoluted tubule (DCT) plays an essential role in sodium and potassium homeostasis. Here, we demonstrate that NCC activity is increased by the β2-adrenoceptor agonist salbutamol, a drug prevalently used to treat asthma. Relative to β1-adrenergic receptors, the β2-adrenergic receptors were greatly enriched in mouse DCT cells. In mice, administration of salbutamol increased NCC phosphorylation (indicating increased activity) within 30 minutes but also caused hypokalemia, which also increases NCC phosphorylation.
      Citation: Kidney International (2021)
      PubDate: 2021-04-30
      DOI: 10.1016/j.kint.2021.04.021
  • Trends and impact on cold ischemia time and clinical outcomes using
           virtual crossmatch for deceased donor kidney transplantation in the United
    • Authors: Chethan M. Puttarajappa; Dana Jorgensen, Jonathan G. Yabes, Kwonho Jeong, Adriana Zeevi, John Lunz, Amit D. Tevar, Michele Molinari, Sumit Mohan, Sundaram Hariharan
      Abstract: For assessing human leukocyte antigen compatibility in deceased donor kidney transplantation, virtual crossmatch is used as an alternative to physical crossmatch and has potential to reduce cold ischemia time. The 2014 United States kidney allocation system prioritized highly sensitized candidates but led to increased shipping of kidneys. Using data from the Scientific Registry of Transplant Recipients, we evaluated changes in virtual crossmatch use with the new allocation policy and the impact of virtual crossmatch use on cold ischemia time and transplant outcomes.
      Citation: Kidney International (2021)
      PubDate: 2021-04-29
      DOI: 10.1016/j.kint.2021.04.020
  • Refining genotype-phenotype correlations in 304 patients with autosomal
           recessive polycystic kidney disease and PKHD1 gene variants.
    • Authors: Kathrin Burgmaier; Leonie Brinker, Florian Erger, Bodo Beck, Marcus Benz, Carsten Bergmann, Olivia Boyer, Laure Collard, Claudia Dafinger, Marc Fila, Claudia Kowalewska, Bärbel Lange-Sperandio, Laura Massella, Antonio Mastrangelo, Djalila Mekahli, Monika Miklaszewska, Nadina Ortiz-Bruechle, Ludwig Patzer, Larisa Prikhodina, Bruno Ranchin, Nadejda Ranguelov, Raphael Schild, Tomas Seeman, Lale Sever, Przemyslaw Sikora, Maria Szczepanska, Ana Teixeira, Julia Thumfart, Barbara Uetz, Lutz Thorsten Weber, Elke Wühl, Klaus Zerres, ESCAPE Study group, GPN study group, Jörg Dötsch, Franz Schaefer, Max Christoph Liebau, ARegPKD consortium
      Abstract: Autosomal recessive polycystic kidney disease (ARPKD) is a severe disease of early childhood that is clinically characterized by fibrocystic changes of the kidneys and the liver. The main cause of ARPKD are variants in the PKHD1 gene encoding the large transmembrane protein fibrocystin. The mechanisms underlying the observed clinical heterogeneity in ARPKD remain incompletely understood, partly due to the fact that genotype-phenotype correlations have been limited to the association of biallelic null variants in PKHD1 with the most severe phenotypes.
      Citation: Kidney International (2021)
      PubDate: 2021-04-29
      DOI: 10.1016/j.kint.2021.04.019
  • The prevalence of pain among patients with chronic kidney disease using
           systematic review and meta-analysis
    • Authors: Emilie Lambourg; Lesley Colvin, Greg Guthrie, Kiruthikka Murugan, Michelle Lim, Heather Walker, Georgia Boon, Samira Bell
      Abstract: Pain is a common but often undertreated symptom in patients with chronic kidney disease (CKD) with a much higher prevalence than in the general population. The aim of this systematic review was to synthesize all available quantitative evidence, in order to gain a better understanding of pain prevalence and pain types in patients with CKD. Four databases and the grey literature were searched until 15th January 2021. Random-effect meta-analyses were conducted with multiple subgroup analyses and meta-regressions to further explore the between-study heterogeneity.
      Citation: Kidney International (2021)
      PubDate: 2021-04-29
      DOI: 10.1016/j.kint.2021.03.041
  • Disparity between levels of anti-RBD IgG and anti-nucleocapsid protein IgG
           antibodies in Covid-19 recovered kidney transplant patients
    • Authors: Chih-Chao Chang; George Vlad, Elena-Rodica Vasilescu, Syed A. Husain, Ya Nan Liu, Wei-Zen Sun, Ming-Fu Chang, Nicole Suciu-Foca, Sumit Mohan
      Abstract: We read with great interest Chavarot’s1 study, demonstrating anti-SARS-CoV-2 anti-nucleocapsid (N) protein IgG decline rapidly following SARS-CoV2 infection in kidney transplant patients (KTx-pts), independent of illness severity, but it did not address the dynamic interplay with IgG antibodies against the spike protein Receptor Binding Domain (Spike-RBD).
      Citation: Kidney International (2021)
      PubDate: 2021-04-29
      DOI: 10.1016/j.kint.2021.04.018
  • Acute rejection after anti-SARS-CoV-2 mRNA vaccination in a
           kidney-transplant patient
    • Authors: Arnaud Del Bello; Olivier Marion, Audrey Delas, Nicolas Congy-Jolivet, Magali Colombat, Nassim Kamar
      Abstract: Anti-Severe Acute Respiratory Syndrome coronavirus-2 (SARS-CoV-2) vaccination is recommended in transplant-patients because of increased risk of developing severe coronavirus disease-19 (COVID-19), and mortality 1. Because of a weak immunogenicity of mRNA two-doses vaccines in transplant-patients, the French Health Authority recommended to offer a third dose to immunosuppressed patients to boost the immune response 2 3. However, no biological monitoring before and after vaccination is recommended.
      Citation: Kidney International (2021)
      PubDate: 2021-04-28
      DOI: 10.1016/j.kint.2021.04.025
  • The inflammatory state is a risk factor for cardiovascular disease and
           graft fibrosis in kidney transplantation.
    • Authors: Ponticelli Claudio; Campise Maria Rosaria
      Abstract: Several factors such as donor brain death, ischemia-reperfusion injury, rejection, infection, and chronic allograft dysfunction may induce an inflammatory state in kidney transplantation. Furthermore, inflammatory cells, cytokines, growth factors, complement and coagulation cascade create an unbalanced interaction with innate and adaptive immunity which are both heavily involved in atherogenesis. The crosstalk between inflammation and thrombosis may lead to prothrombotic state and impaired fibrinolysis in kidney transplant recipients increasing the risk of cardiovascular disease.
      Citation: Kidney International (2021)
      PubDate: 2021-04-28
      DOI: 10.1016/j.kint.2021.04.016
  • A case of gross hematuria and IgA Nephropathy Flare up following
           SARS-CoV-2 vaccination
    • Authors: Shab E. Gul Rahim; Jonathan Lin, John C. Wang
      Abstract: We read with great interest L. Negrea, et al’s report of 2 cases of IgA nephropathy (IgAN) with gross hematuria following the Moderna vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1. We also cared for a 52-year-old Asian female with prior biopsy-proven IgAN who developed gross hematuria within 24 hours of receiving a second dose of the Pfizer vaccine. Table 1 summarizes clinical data. Her work-up was notable for proteinuria of 4.2g/g of creatinine with serum creatinine at baseline.
      Citation: Kidney International (2021)
      PubDate: 2021-04-27
      DOI: 10.1016/j.kint.2021.04.024
  • Use of Peritoneal Dialysis for Acute Kidney Injury during the COVID-19
           Pandemic in New York City: A multicenter observational study
    • Authors: Wei Chen; Nina Caplin, Osama El Shamy, Shuchita Sharma, Maryanne Y. Sourial, Michael J. Ross, Mina H. Sourial, Kalyan Prudhvi, Ladan Golestaneh, Vesh Srivatana, Rochelle Dalsan, Daniil Shimonov, Luis Sanchez-Russo, Sara Atallah, Jaime Uribarri, NYC-PD Consortium
      Abstract: To demonstrate feasibility of acute peritoneal dialysis (PD) for acute kidney injury during the coronavirus disease 2019 (COVID-19) pandemic, we performed a multicenter, retrospective, observational study of 94 patients who received acute PD in New York City in the Spring of 2020. Patient comorbidities, severity of disease, laboratory values, kidney replacement therapy (KRT), and patient outcomes were recorded. Mean age was 61±11 years; 34% were women; 94% had confirmed COVID-19; 32% required mechanical ventilation on admission.
      Citation: Kidney International (2021)
      PubDate: 2021-04-27
      DOI: 10.1016/j.kint.2021.04.017
  • Tissue-resident macrophages mediate neutrophil recruitment and kidney
           injury in shiga toxin-induced hemolytic uremic syndrome.
    • Authors: Julia K. Lill; Stephanie Thiebes, Judith-Mira Pohl, Jenny Bottek, Nirojah Subramaniam, Robin Christ, Camille Soun, Faikah Gueler, Denise Zwanziger, Franziska Hoffmann, Ferdinand von Eggeling, Thilo Bracht, Barbara Sitek, Michael J. Hickey, Oliver Hofnagel, Daniel R. Engel
      Abstract: Enterohaemorrhagic E. coli cause major epidemics worldwide with significant organ damage and very high percentages of death. Due to the ability of enterohaemorrhagic E. coli to produce shiga toxin these bacteria damage the kidney leading to the hemolytic uremic syndrome. A therapy against this serious kidney disease has not been developed yet and the impact and mechanism of leukocyte activation and recruitment are unclear. Tissue-resident macrophages represent the main leukocyte population in the healthy kidney, but the role of this important cell population in shiga toxin-producing E.
      Citation: Kidney International (2021)
      PubDate: 2021-04-27
      DOI: 10.1016/j.kint.2021.03.039
  • Apolipoprotein-1 risk variants and associated kidney phenotypes in an
           adult HIV cohort in Nigeria.
    • Authors: Usman J. Wudil; Muktar H. Aliyu, Heather L. Prigmore, Donna J. Ingles, Aima A. Ahonkhai, Baba M. Musa, Hamza Muhammad, Mahmoud U. Sani, Aisha M. Nalado, Aliyu Abdu, Kabiru Abdussalam, Bryan E. Shepherd, Faisal S. Dankishiya, Anna M. Burgner, Talat A. Ikizler, Christina M. Wyatt, Jeffrey B. Kopp, Paul L. Kimmel, Cheryl A. Winkler, C. William Wester
      Abstract: HIV-positive adults are at risk for various kidney diseases, and apolipoprotein 1 (APOL1) high-risk genotypes increase this risk. This study aimed to determine the prevalence and ethnic distribution of APOL1 risk genotypes among a cohort of HIV-positive Nigerian adults and explore the relationship between APOL1 risk variant status with albuminuria and estimated glomerular filtration rate (eGFR). We conducted a cross-sectional study among 2 458 persons living with HIV who attended an HIV clinic in northern Nigeria and had received antiretroviral therapy for a minimum of six months.
      Citation: Kidney International (2021)
      PubDate: 2021-04-23
      DOI: 10.1016/j.kint.2021.03.038
  • Neutralizing SARS-CoV-2 antibody response in dialysis patients after the
           first dose of the BNT162b2 mRNA Covid-19 vaccine. The war is far from
           being won.
    • Authors: Massimo Torreggiani; Sophie Blanchi, Antioco Fois, Hafedh Fessi, Giorgina Barbara Piccoli
      Abstract: On December 21, 2020, the European Commission granted conditional marketing approval to the BNT162b2 Covid-19 mRNA vaccine developed by BioNTech.1,2 In the general population, the first dose of BNT162b2 was reported to produce a rapid antibody response with 52% efficacy in preventing severe infection, similar to the protection induced by the natural disease.2,3 There was great hope that vaccination would protect fragile individuals and societies of nephrology asked that patients with end-stage kidney disease should be given priority in being vaccinated.
      Citation: Kidney International (2021)
      PubDate: 2021-04-19
      DOI: 10.1016/j.kint.2021.04.010
  • SARS-CoV-2-reactive cellular and humoral immunity in hemodialysis
    • Authors: Moritz Anft; Arturo Blazquez-Navarro, Krystallenia Paniskaki, Sarah Skrzypczyk, Heiner Appel, Thiemo Pfab, Andrea Uhle, Michael Frahnert, Michael Barenbrock, Eckhard Büssemaker, Jan Hörstrup, Adrian Doevelaar, Felix S. Seibert, Bodo Hölzer, Ulrik Stervbo, Sebastian Dolff, Oliver Witzke, Nina Babel, Timm H. Westhoff
      Abstract: The outcome of SARS-CoV-2 infection in hemodialysis (HD) patients is significantly worse compared to the general population1-3. Whether the SARS-CoV-2-specific immunity in dialysis patients with COVID-19 is impaired as a possible cause for the inferior outcome is not known so far.
      Citation: Kidney International (2021)
      PubDate: 2021-04-19
      DOI: 10.1016/j.kint.2021.03.032
  • Antibody response to BNT162b2 vaccine in maintenance hemodialysis patients
    • Authors: Philippe Attias; Hamza Sakhi, Philippe Rieu, Arvish Soorkia, David Assayag, Sabrina Bouhroum, Patrice Nizard, Khalil El Karoui
      Abstract: Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Service de Néphrologie et Transplantation, Centre de Référence Maladie Rare « Syndrome Néphrotique Idiopathique », Fédération Hospitalo-Universitaire « Innovative therapy for immune disorders », Créteil, France.
      Citation: Kidney International (2021)
      PubDate: 2021-04-19
      DOI: 10.1016/j.kint.2021.04.009
  • Seroprevalence of antibody to S1 spike protein following vaccination
           against COVID-19 in patients on haemodialysis. A call to arms
    • Authors: R.E. Billany; H. Selvaskandan, S.F. Adenwalla, Kl Hull, D.S. March, J.O. Burton, N.C. Bishop, E.J. Carr, R. Beale, J.W. Tang, P.W. Bird, C.W. Holmes, R. Baines, N.J. Brunskill, M.P. Graham-Brown
      Abstract: Adult patients with end-stage kidney disease (ESKD) on haemodialysis are at increased risk of coronavirus disease 2019 (COVID-19) infection and death (1). This group is often multi-racial, suffer from many comorbidities and can be socio-economically deprived; all factors strongly associated with COVID-19 mortality (1). Vaccination is a priority for this at risk group who are relatively immunosuppressed and the effectiveness of vaccines have not been explicitly tested in patients with chronic kidney disease and on dialysis, meaning vaccine efficacy or immunogenicity is not well understood (2).
      Citation: Kidney International (2021)
      PubDate: 2021-04-19
      DOI: 10.1016/j.kint.2021.04.008
  • Immune response to SARS-CoV2 infection and vaccination in patients
           receiving kidney replacement therapy
    • Authors: T. Alp Ikizler; P. Toby Coates, Brad Rovin, Pierre Ronco
      Abstract: In this issue of the Journal, the initial experience regarding the immunogenicity of prior COVID-19 infection and the response to the COVID-19 vaccines among patients on maintenance dialysis and kidney transplant recipients is summarized. Preliminary data suggest that there is reasonable durability of immune response after COVID19 infection. While immune response to first dose of vaccine is less than acceptable in both groups, a significant portion of maintenance dialysis patients develop robust antibody titers whereas kidney transplant recipients show a less strong immune response even after 2nd vaccine dose.
      Citation: Kidney International (2021)
      PubDate: 2021-04-19
      DOI: 10.1016/j.kint.2021.04.007
  • Experience with SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients
    • Authors: Noa Berar Yanay; Sarit Freiman, Ma'anit Shapira, Samar Wishahi, Munir Hamze, Mohamad Elhaj, Maha Zaher, Zaher Armaly
      Abstract: The immune system is profoundly affected by uremia. End stage kidney disease (ESKD) patients may be more vulnerable to infections and may have suboptimal response to vaccination1. For the SARS-COV-2 (COVID-19), patients with ESKD are at increased risk of infection and mortality 2-4. The first emergency use authorizations for COVID-19 vaccines were granted by the FDA in December 2020, and clinical trials for the approval of more vaccines are ongoing. However, the representation of patients with CKD and ESKD in these trials is low or unreported 5.
      Citation: Kidney International (2021)
      PubDate: 2021-04-19
      DOI: 10.1016/j.kint.2021.04.006
  • Low immunization rates among kidney transplant recipients who received two
           doses of the mRNA-1273 SARS-CoV-2 vaccine
    • Authors: Ilies Benotmane; Gabriela Gautier -Vargas, Noelle Cognard, Jerome Olagne, Francoise Heibel, Laura Braun-Parvez, Jonas Martzloff, Peggy Perrin, Bruno Moulin, Samira Fafi-Kremer, Sophie Caillard
      Abstract: The efficacy rates of vaccines to prevent infection with SARS-CoV-2 have not been specifically investigated in kidney transplant recipient (KTRs). Preliminary results suggest that among KTRs who received the first injection of an mRNA-based vaccine the antibody response is weak.1,2 This study reports on the immunization rates of KTRs who received two doses of the mRNA-1273 SARS-CoV-2 vaccine (Moderna, Cambridge, MA, USA).3
      Citation: Kidney International (2021)
      PubDate: 2021-04-19
      DOI: 10.1016/j.kint.2021.04.005
  • A pre-specified analysis of the DAPA-CKD trial indicates effects of
           dapagliflozin on major adverse kidney events in patients with IgA
    • Authors: David C. Wheeler; Robert D. Toto, Bergur V. Stefansson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Roberto Pecoits-Filho, Ricardo Correa-Rotter, Peter Rossing, C. David Sjöström, Kausik Umanath, Anna Maria Langkilde, Hiddo J.L. Heerspink, DAPA-CKD Trial Committees Investigators
      Abstract: Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite use of renin-angiotensin-aldosterone-system blockers and immunosuppressants, often progresses to kidney failure. In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease trial, dapagliflozin reduced risk of kidney failure and prolonged survival in participants with chronic kidney disease with and without type 2 diabetes, including those with IgA nephropathy. Here we randomized participants with estimated glomerular filtration rate (eGFR) 25-75 mL/min/1.73m2 and urinary albumin-to-creatinine ratio 200-5000 mg/g (22.6-565 mg/mol) to dapagliflozin 10mg or placebo, as adjunct to standard care The primary composite endpoint was a sustained decline in eGFR of 50% or more, end-stage kidney disease, or death from a kidney disease-related or cardiovascular cause.
      Citation: Kidney International (2021)
      PubDate: 2021-04-17
      DOI: 10.1016/j.kint.2021.03.033
  • SGLT-2 inhibition in IgA nephropathy: the new standard-of-care'
    • Authors: Jonathan Barratt; Jürgen Floege
      Abstract: Despite supportive measures that slow the rate of progression of chronic kidney disease in IgA nephropathy (IgAN) many patients still progress to end stage kidney disease. Currently employed immunosuppressive strategies lack conclusive efficacy data, while there is evidence for treatment emergent toxicity. A subanalysis of the DAPA-CKD trial, which encompassed 270 patients with a diagnosis of IgAN, now provides early evidence that dapagliflozin may be a safe and effective addition to current standard of care in IgAN.
      Citation: Kidney International (2021)
      PubDate: 2021-04-16
      DOI: 10.1016/j.kint.2021.04.002
  • A report from the European Hyperoxaluria Consortium (OxalEurope) Registry
           on a large cohort of patients with primary hyperoxaluria type 3.
    • Authors: Cristina Martin-Higueras; Sander F. Garrelfs, Jaap W. Groothoff, Dorrit Jacob, Shabbir H. Moochhala, Justine Bacchetta, Cecile Acquaviva, Marcin Zaniew, Przymyslaw Sikora, Bodo B. Beck, Bernd Hoppe
      Abstract: Outcome data in primary hyperoxaluria type 3 (PH3), described as a less severe form of the PH’s with a low risk of chronic kidney disease, are scarce. To investigate this, we retrospectively analyzed the largest PH3 cohort reported so far. Of 95 patients, 74 were followed over a median of six years. Median age of first symptoms and diagnosis were 1.9 and 6.3 years, respectively. Urolithiasis was the major clinical feature observed in 70% of pediatric and 50% of adult patients. At most recent follow-up available for 56 of the 95 patients, 21.4% were in chronic kidney disease stages 2 or more.
      Citation: Kidney International (2021)
      PubDate: 2021-04-15
      DOI: 10.1016/j.kint.2021.03.031
  • Anti-neutrophil cytoplasmic antibody associated glomerulonephritis
           complicating treatment with hydralazine.
    • Authors: Dominick Santoriello; Andrew S. Bomback, Satoru Kudose, Ibrahim Batal, M. Barry Stokes, Pietro Canetta, Jai Radhakrishnan, Gerald B. Appel, Vivette D. D’Agati, Glen S. Markowitz
      Abstract: Hydralazine, a widely used therapy for hypertension and heart failure, can elicit autoimmunedisease, including anti-neutrophil cytoplasmic antibody associated glomerulonephritis (ANCA-GN). We identified 80 cases of ANCA-GN complicating treatment with hydralazine, accounting for 4.3% (80/1858 biopsies) of ANCA-GN diagnosed between 2006 and 2019. Over three-fourths of patients were on hydralazine for at least one year, with mean daily dose of approximately 250 mg/day. ANCA testing revealed p-ANCA/myeloperoxidase-ANCA seropositivity in 98%, including 39% with dual p-ANCA/myeloperoxidase-ANCA and cANCA/anti-protinase 3-ANCA positivity, often accompanied by anti-nuclear antibody (89%), anti-histone antibody (98%), and hypocomplementemia (58%).
      Citation: Kidney International (2021)
      PubDate: 2021-04-12
      DOI: 10.1016/j.kint.2021.03.029
  • Metabolic Needs of the Kidney Graft undergoing Normothermic Machine
    • Authors: Asel S. Arykbaeva; Dorottya K. de Vries, Jason B. Doppenberg, Marten A. Engelse, Thomas Hankemeier, Amy C. Harms, Leonie G. Wijermars, Alexander F. Schaapherder, Jaap A. Bakker, Rutger J. Ploeg, Ian P.J. Alwayn, Jan H.N. Lindeman
      Abstract: Normothermic machine perfusion (NMP) is emerging as a novel preservation strategy. During NMP, the organ is maintained in a metabolically active state that may not only provide superior organ preservation, but which also facilitates viability testing prior to transplantation, and ex-situ resuscitation of marginal kidney grafts. While the prevailing perfusion protocols for renal NMP are refined from initial pioneering studies concerning short periods of NMP, it could be argued that these protocols are not optimally tailored to address the putatively compromised metabolic plasticity of marginal donor grafts (i.e.
      Citation: Kidney International (2021)
      PubDate: 2021-04-12
      DOI: 10.1016/j.kint.2021.04.001
  • A conceptual framework linking immunology, pathology, and clinical
           features in primary membranous nephropathy
    • Authors: Gabriel B. Lerner; Samarth Virmani, Joel M. Henderson, Jean M. Francis, Laurence H. Beck
      Abstract: Primary membranous nephropathy (PMN) is a leading cause of adult nephrotic syndrome. The field took a major step forward with the identification of phospholipase A2 receptor (PLA2R) as target antigen in the majority of cases and with the ability to measure circulating autoantibodies to this protein (aPLA2R). Since then, the existence of additional target antigens such as thrombospondin type-1 domain containing 7A, exostosin 1 and 2, NELL-1, Semaphorin-3B has been demonstrated. The ability to detect and monitor levels of circulating autoantibodies has opened a new window onto the humoral aspect of PMN.
      Citation: Kidney International (2021)
      PubDate: 2021-04-12
      DOI: 10.1016/j.kint.2021.03.028
  • Controversies in Optimal Anemia Management: Conclusions from a Kidney
           Disease Improving Global Outcomes (KDIGO) Conference
    • Authors: Jodie L. Babitt; Michele F. Eisenga, Volker H. Haase, Abhijit V. Kshirsagar, Adeera Levin, Francesco Locatelli, Jolanta Małyszko, Dorine W. Swinkels, Der-Cherng Tarng, Michael Cheung, Michel Jadoul, Wolfgang C. Winkelmayer, Tilman B. Drüeke, for Conference Participants
      Abstract: In chronic kidney disease (CKD), anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluation, and treatment of anemia in CKD. Since then, new data have accrued from basic research, epidemiological studies, and randomized trials that warrant a re-examination of previous recommendations. Therefore, in 2019, KDIGO decided to convene two Controversies Conferences to review the latest evidence, explore new and ongoing controversies, assess change implications for the current KDIGO anemia guideline, and propose a research agenda.
      Citation: Kidney International (2021)
      PubDate: 2021-04-08
      DOI: 10.1016/j.kint.2021.03.020
  • A randomized controlled trial to investigate the effects of intra-dialytic
           cycling on left ventricular mass
    • Authors: Matthew P.M. Graham-Brown; Daniel S. March, Robin Young, Patrick J. Highton, Hannah M.L. Young, Darren R. Churchward, Maurice Dungey, David J. Stensel, Nicolette C. Bishop, Nigel J. Brunskill, Alice C. Smith, Gerry P. McCann, Alex McConnachie, James O. Burton
      Abstract: Cardiovascular disease is the leading cause of death for patients receiving hemodialysis. Since exercise mitigates many risk factors which drive cardiovascular disease for these patients, we assessed effects of a program of intra-dialytic cycling on left ventricular mass and other prognostically relevant measures of cardiovascular disease as evaluated by cardiac MRI (the CYCLE-HD trial). This was a prospective, open-label, single-blinded cluster-randomized controlled trial powered to detect a 15g difference in left ventricular mass measured between patients undergoing a six-month program of intra-dialytic cycling (exercise group) and patients continuing usual care (control group).
      Citation: Kidney International (2021)
      PubDate: 2021-04-08
      DOI: 10.1016/j.kint.2021.02.027
  • Chronic active T cell-mediated rejection is variably responsive to
           immunosuppressive therapy.
    • Authors: Vanderlene L. Kung; Rana Sandhu, Mark Haas, Edmund Huang
      Abstract: Chronic active T cell-mediated rejection (CA TCMR) is a newly described variant of kidney allograft rejection associated with long-term graft loss. Whether this form of rejection is related to under immunosuppression is debated and the benefit of immunosuppressive therapy in CA TCMR is unknown. Here we investigate the amenability of CA TCMR to treatment and examine the impact of clinical, histologic, and molecular parameters on outcomes. In a retrospective single institution review, we identified 48 cases of isolated CA TCMR, of which 44 were treated with pulse steroids and/or anti-thymocyte globulin.
      Citation: Kidney International (2021)
      PubDate: 2021-04-07
      DOI: 10.1016/j.kint.2021.03.027
  • Genome-wide association study of serum metabolites in the African American
           Study of Kidney Disease and Hypertension
    • Authors: Shengyuan Luo; Elena V. Feofanova, Adrienne Tin, Sarah Tung, Eugene P. Rhee, Josef Coresh, Dan E. Arking, Aditya Surapaneni, Pascal Schlosser, Yong Li, Anna Köttgen, Bing Yu, Morgan E. Grams
      Abstract: The genome-wide association study (GWAS) is a powerful means to study genetic determinants of disease traits and generate insights into disease pathophysiology. To date, few GWAS of circulating metabolite levels have been performed in African Americans with chronic kidney disease. Hypothesizing that novel genetic-metabolite associations may be identified in a unique population of African Americans with a lower glomerular filtration rate (GFR), we conducted a GWAS of 652 serum metabolites in 619 participants (mean measured glomerular filtration rate 45 mL/min/1.73m2) in the African American Study of Kidney Disease and Hypertension, a clinical trial of blood pressure lowering and antihypertensive medication in African Americans with chronic kidney disease.
      Citation: Kidney International (2021)
      PubDate: 2021-04-07
      DOI: 10.1016/j.kint.2021.03.026
  • A small molecule inhibitor of the chloride channel TMEM16A blocks vascular
           smooth muscle contraction and lowers blood pressure in spontaneously
           hypertensive rats.
    • Authors: Onur Cil; Xiaolan Chen, Henry R. Askew Page, Samuel N. Baldwin, Maria C. Jordan, Pyone Myat Thwe, Marc O. Anderson, Peter M. Haggie, Iain A. Greenwood, Kenneth P. Roos, Alan S. Verkman
      Abstract: Hypertension is a major cause of cardiovascular morbidity and mortality, despite the availability of antihypertensive drugs with different targets and mechanisms of action. Here, we provide evidence that pharmacological inhibition of TMEM16A (ANO1), a calcium-activated chloride channel expressed in vascular smooth muscle cells, blocks calcium-activated chloride currents and contraction in vascular smooth muscle in vitro and decreases blood pressure in spontaneously hypertensive rats. The acylaminocycloalkylthiophene TMinh-23 fully inhibited calcium-activated TMEM16A chloride current with nanomolar potency in Fischer rat thyroid cells expressing TMEM16A, and in primary cultures of rat vascular smooth muscle cells.
      Citation: Kidney International (2021)
      PubDate: 2021-04-05
      DOI: 10.1016/j.kint.2021.03.025
  • Epithelial proliferation and cell cycle dysregulation in kidney injury and
    • Authors: Kyung Lee; G. Luca Gusella, John Cijiang He
      Abstract: Various cellular insult and injury to renal epithelial cells stimulate repair mechanisms to adapt and restore the organ homeostasis. Renal tubular epithelial cells (RTECs) are endowed with regenerative capacity, which allows for a restoration of nephron function after acute kidney injury (AKI). However, recent evidence indicates that the repair is often incomplete, leading to maladaptive responses that promote the progression to CKD. The dysregulated cell cycle and proliferation is also a key feature of RTECs in polycystic kidney disease (PKD) and HIV-associated nephropathy (HIVAN).
      Citation: Kidney International (2021)
      PubDate: 2021-04-05
      DOI: 10.1016/j.kint.2021.03.024
  • Amelioration of chronic kidney disease-associated anemia by vadadustat in
           mice is not dependent on erythroferrone.
    • Authors: Mark R. Hanudel; Shirley Wong, Grace Jung, Bo Qiao, Victoria Gabayan, Anna Zuk, Tomas Ganz
      Abstract: Vadadustat is an investigational hypoxia-inducible factor prolyl hydroxylase inhibitor that increases endogenous erythropoietin production, and has been shown to decrease hepcidin levels, ameliorate iron restriction, and increase hemoglobin concentrations in anemic patients with chronic kidney disease (CKD). In studies of physiological responses to other erythropoietic stimuli, erythropoietin induced erythroblast secretion of erythroferrone (ERFE), which acts on the liver to suppress hepcidin production and mobilize iron for erythropoiesis.
      Citation: Kidney International (2021)
      PubDate: 2021-03-31
      DOI: 10.1016/j.kint.2021.03.019
  • Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not
           kidney fibrosis
    • Authors: Szu-Yu Pan; Pei-Zhen Tsai, Yu-Hsiang Chou, Yu-Ting Chang, Fan-Chi Chang, Yen-Ling Chiu, Wen-Chih Chiang, Tien Hsu, Yung-Ming Chen, Tzong-Shinn Chu, Shuei-Liong Lin
      Abstract: Prolyl hydroxylase domain enzyme (PHD) inhibitors are effective in the treatment of chronic kidney disease (CKD)-associated anemia by stabilizing hypoxia inducible factor (HIF), thereby increasing erythropoietin and consequently erythropoiesis. However, concern for CKD progression needs to be addressed in clinical trials. Although pre-clinical studies showed an anti-inflammatory effect in kidney disease models, the effect of PHD inhibitors on kidney fibrosis was inconsistent probably because the effects of HIF are cell type and context dependent.
      Citation: Kidney International (2021)
      PubDate: 2021-03-31
      DOI: 10.1016/j.kint.2021.01.017
  • Inferring Causality from Observational Studies: The Role of Instrumental
           Variable Analysis
    • Authors: Rui Fu; S. Joseph Kim
      Abstract: Inferring causality from observational studies can be challenging because of the perennial threat of biases from selection, measurement, and confounding. The gold standard study design in clinical research is the randomized controlled trial, since random allocation to treatment ensures that, on average, comparison groups are balanced with respect to both known and unknown prognostic factors. However, most clinically relevant exposure-outcome relationships are not amendable (logistically or ethically) to randomization.
      Citation: Kidney International (2021)
      PubDate: 2021-03-30
      DOI: 10.1016/j.kint.2021.03.018
  • APOL1 at ten years: Progress and next steps
    • Authors: Barry I. Freedman; Jeffrey B. Kopp, Matthew G. Sampson, Katalin Susztak
      Abstract: APOL1 kidney risk variants (RVs) were identified in 2010 as major drivers of glomerular, tubulointerstitial and renal microvascular disease in individuals with sub-Saharan African ancestry. In December 2020, the “APOL1 at Ten” conference summarized the first decade of progress and discussed controversies and uncertainties that remain to be addressed. Topics included trypanosome infection and its role in the evolution of APOL1 kidney RVs, clinical phenotypes in APOL1-associated nephropathy, relationships between APOL1 RVs and background haplotypes on cell injury and molecular mechanisms initiating disease, the role of clinical APOL1 genotyping, and development of novel therapies for kidney disease.
      Citation: Kidney International (2021)
      PubDate: 2021-03-29
      DOI: 10.1016/j.kint.2021.03.013
  • From Kidney Injury to Kidney Cancer
    • Authors: Anna Julie Peired; Elena Lazzeri, Francesco Guzzi, Hans-Joachim Anders, Paola Romagnani
      Abstract: Epidemiological studies document strong associations between acute or chronic kidney injury and kidney tumors. However, whether these associations are linked by causation, and in which direction, is unclear. Accumulating data from basic and clinical research now shed light on this issue and prompt us to propose a new pathophysiological concept with immanent implications in the management of patients with kidney disease and patients with kidney tumors. As a central paradigm, this review proposes the mechanisms of kidney damage and repair that are active during acute kidney injury but also during persistent injuries in chronic kidney disease as triggers of DNA damage promoting the expansion of (pre-)malignant cell clones.
      Citation: Kidney International (2021)
      PubDate: 2021-03-29
      DOI: 10.1016/j.kint.2021.03.011
  • A multicenter randomized controlled trial indicates that paclitaxel-coated
    • Authors: Narayan Karunanithy; Emily J. Robinson, Farhan Ahmad, James O. Burton, Francis Calder, Simon Coles, Neelanjan Das, Anthony Dorling, Colin Forman, Ounali Jaffer, Sarah Lawman, Raghuram Lakshminarayan, Rhys Lewlellyn, Janet L. Peacock, Raymond Ramnarine, Irene Rebollo Mesa, Shoaib Shaikh, James Simpson, Kate Steiner, Rebecca Suckling, Laszlo Szabo, Douglas Turner, Ashar Wadoodi, Yanzhong Wang, Graeme Weir, C.Jason Wilkins, Leanne M. Gardner, Michael G. Robson
      Abstract: The role of paclitaxel-coated balloons has been established in the coronary and peripheral arterial circulations with recent interest in the use of paclitaxel-coated balloons to improve patency rates following angioplasty of arteriovenous fistulas. To assess the efficacy of paclitaxel-coated angioplasty balloons to prolong the survival time of target lesion primary patency in arteriovenous fistulas, we designed an investigator-led multi-center randomized controlled trial with follow up time variable for a minimum of one year.
      Citation: Kidney International (2021)
      PubDate: 2021-03-26
      DOI: 10.1016/j.kint.2021.02.040
  • Blockade of tumor necrosis factor superfamily members CD30 and OX40
           abrogates disease activity in murine immune-mediated glomerulonephritis.
    • Authors: Katharina Artinger; Alexander H. Kirsch, Agnes A. Mooslechner, Daniel J. Cooper, Ida Aringer, Max Schuller, Corinna Schabhüttl, Konstantin A. Klötzer, Kerstin Schweighofer, Philipp Eller, Hideo Yagita, Anna L. Illert, Alexander R. Rosenkranz, Peter J. Lane, Kathrin Eller
      Abstract: Co-stimulation is a prerequisite for pathogenic activity in T cell-mediated diseases and has been demonstrated to achieve tolerance in organ-specific autoimmunity as a therapeutic target. Here, we evaluated the involvement of the tumor necrosis factor family members CD30 and OX40 in immune-complex mediated kidney disease. In vitro stimulation and proliferation studies were performed with CD4+ cells from wild type and CD30/OX40 double knock-out (CD30OX40-/-) mice. In vivo studies were performed by induction of nephrotoxic serum nephritis in wild type, CD30OX40- /- , CD30-/-, OX40-/-, reconstituted Rag1-/- and C57Bl/6J mice treated with αCD30L αOX40L antibodies.
      Citation: Kidney International (2021)
      PubDate: 2021-03-26
      DOI: 10.1016/j.kint.2021.02.039
  • Hepatorenal Syndrome: A historical appraisal of its origins and conceptual
    • Authors: Garabed Eknoyan; Murray Epstein
      Abstract: The hepatorenal syndrome (HRS), a progressive but potentially reversible deterioration of kidney function constitutes a serious complication of hepatic decompensation. Coexistence of liver/kidney damage, mentioned in the dropsy literature, was highlighted by Richard Bright in 1827 and confirmed in 1840 by his contemporary nephrology pioneer Pierre Rayer. Cholemic nephrosis was described in 1861 by Friedrich Frerichs, and the renal tubular lesions of HRS by Austin Flint in 1863. The term ‘acute hepato-nephritis’ was introduced in 1916 by Paul Merklen and its chronic form designated HRS by Marcel Dérot in 1930s.
      Citation: Kidney International (2021)
      PubDate: 2021-03-26
      DOI: 10.1016/j.kint.2021.02.037
  • Weak anti-SARS-CoV-2 antibody response after the first injection of an
           mRNA COVID-19 vaccine in kidney transplant recipients
    • Authors: Ilies Benotmane; Gabriela Gautier -Vargas, Noelle Cognard, Jerome Olagne, Francoise Heibel, Laura Braun-Parvez, Jonas Martzloff, Peggy Perrin, Bruno Moulin, Samira Fafi-Kremer, Sophie Caillard
      Abstract: International recommendations on COVID-19 vaccine distribution have given priority to immunocompromised patients – including kidney transplant recipients (KTRs).1,2 Unfortunately, this guidance has been released without inclusion of this clinical population in vaccine clinical trials. In an effort to shed light on the efficacy and safety of an mRNA COVID-19 vaccine in KTRs, this preliminary study was undertaken to investigate the anti-SARS-CoV-2 antibody response after the first injection.
      Citation: Kidney International (2021)
      PubDate: 2021-03-25
      DOI: 10.1016/j.kint.2021.03.014
  • Complement in membranous nephropathy: what we thought we knew and what we
           really know
    • Authors: Paolo Cravedi
      Abstract: Membranous nephropathy (MN), originally called membranous glomerulonephritis, was first described in 1946 by Bell as a glomerular disease characterized by a thickening of the glomerular basement membrane (GBM) and marked proteinuria (Figure 1).1 A series of elegant histopathological analyses and experimental studies in rodents and the isolated perfused kidney system demonstrated that the pathogenesis of this condition involves the deposition of anti-podocyte antibodies in the subepithelial space of the glomeruli, which leads to podocyte injury.
      Citation: Kidney International (2021)
      PubDate: 2021-03-24
      DOI: 10.1016/j.kint.2021.03.010
  • Immunofluorescence Staining for Immunoglobulin Heavy Chain/Light Chain on
           Kidney Biopsies is a Valuable Ancillary Technique For the Diagnosis of
           Monoclonal Gammopathy-Associated Kidney Diseases
    • Authors: Samih H. Nasr; Mary E. Fidler, Samar M. Said, Justin W. Koepplin, Jamie M. Altamirano-Alonso, Nelson Leung
      Abstract: Heavy chain/light chain (HLC) antibodies target conformational epitopes at the junctions of the heavy chain and light chain constant regions (CH1 and CL) of serum IgGκ, IgGλ, IgAκ, IgAλ, IgMκ, and IgMλ to provide quantitation of intact HLC pairs. Here, we developed an HLC tissue immunofluorescence protocol to test if it can complement conventional immunofluorescence in the diagnosis of monoclonal gammopathy-associated kidney diseases. HLC immunofluorescence was performed on archived frozen tissue of 104 kidney biopsies.
      Citation: Kidney International (2021)
      PubDate: 2021-03-24
      DOI: 10.1016/j.kint.2021.02.038
  • Longevity of SARS-CoV-2 immune responses in hemodialysis patients and
           protection against reinfection
    • Authors: Candice L. Clarke; Maria Prendecki, Amrita Dhutia, Jaslyn Gan, Claire Edwards, Virginia Prout, Liz Lightstone, Eleanor Parker, Federica Marchesin, Megan Griffith, Rawya Charif, Graham Pickard, Alison Cox, Myra McClure, Richard Tedder, Paul Randell, Louise Greathead, Mary Guckian, Stephen P. McAdoo, Peter Kelleher, Michelle Willicombe
      Abstract: Patients with end stage kidney disease receiving in-center hemodialysis (ICHD) have had high rates of SARS-CoV-2 infection. Following infection, patients receiving ICHD frequently develop circulating antibodies to SARS-CoV-2, even with asymptomatic infection. Here, we investigated the durability and functionality of the immune responses to SARS-CoV-2 infection in patients receiving ICHD. Three hundred and fifty-six such patients were longitudinally screened for SARS-CoV-2 antibodies and underwent routine PCR-testing for symptomatic and asymptomatic infection.
      Citation: Kidney International (2021)
      PubDate: 2021-03-24
      DOI: 10.1016/j.kint.2021.03.009
  • Gross Hematuria Following Vaccination for SARS-CoV2 in Two Patients with
           IgA Nephropathy
    • Authors: Lavinia Negrea; Brad H. Rovin
      Abstract: To the Editor: Several of the SARS-CoV2 vaccines use a nucleoside-modified, purified mRNA lipid nanoparticle-encapsulated platform. Compared to traditional inactivated viral and adjuvanted protein vaccines, this RNA platform elicits far higher neutralizing antibody titers, stronger antigen-specific CD4+ and CD8+ T cells responses, and stronger germinal center B and TFH cell activation in experimental animals 1. The activated CD4+ and CD8+ T cells produce several proinflammatory cytokines, including interferon-γ and tumor necrosis factor-α.
      Citation: Kidney International (2021)
      PubDate: 2021-03-23
      DOI: 10.1016/j.kint.2021.03.002
  • Inhibition of transforming growth factor β1 signaling in resident
           interstitial cells attenuates profibrotic gene expression and preserves
           erythropoietin production during experimental kidney fibrosis in mice.
    • Authors: Michaela A.A. Fuchs; Katharina A.E. Broeker, Julia Schrankl, Nicolai Burzlaff, Carsten Willam, Charlotte Wagner, Armin Kurtz
      Abstract: Kidney fibrosis is characterized by the development of myofibroblasts originating from resident kidney and immigrating cells. Myofibroblast formation and extracellular matrix production during kidney damage are triggered by various cytokines. Among these, transforming growth factor β1 (TGFβ1) is considered a central trigger for kidney fibrosis. We found a highly upregulated expression of TGFβ1 and TGFβ receptor 2 (TGFβ-R2) mRNAs in kidney interstitial cells in experimental fibrosis. Here, we investigated the contribution of TGFβ1 signaling in resident kidney interstitial cells to organ fibrosis using the models of adenine induced nephropathy and unilateral ureter occlusion in mice.
      Citation: Kidney International (2021)
      PubDate: 2021-03-08
      DOI: 10.1016/j.kint.2021.02.035
  • The genetic background significantly impacts the severity of kidney cystic
           disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic
           kidney disease.
    • Authors: Jennifer Arroyo; Diana Escobar-Zarate, Harrison H. Wells, Megan M. Constans, Ka Thao, Jessica M. Smith, Cynthia J. Sieben, Madeline R. Martell, Timothy L. Kline, Maria V. Irazabal, Vicente E. Torres, Katharina Hopp, Peter C. Harris
      Abstract: Autosomal dominant polycystic kidney disease (ADPKD), primarily due to PKD1 or PKD2 mutations, causes progressive kidney cyst development and kidney failure. There is significant intrafamilial variability likely due to the genetic background and environmental/lifestyle factors; variability that can be modeled in PKD mice. Here, we characterized mice homozygous for the PKD1 hypomorphic allele, p.Arg3277Cys (Pkd1RC/RC), inbred into the BalbC/cJ (BC) or the 129S6/SvEvTac (129) strains, plus F1 progeny bred with the previously characterized C57BL/6J (B6) model; F1(BC/B6) or F1(129/B6).
      Citation: Kidney International (2021)
      PubDate: 2021-03-08
      DOI: 10.1016/j.kint.2021.01.028
  • New Kid on the Block: NOS1AP is a newly recognized genetic cause of
           steroid-resistant nephrotic syndrome in infants
    • Authors: Hua Sun
      Abstract: Steroid-resistant nephrotic syndrome (SRNS) is a rare but important cause of chronic kidney disease and kidney failure in children. Mutations in podocyte genes explain more than two-thirds of early-onset SRNS presenting in the first year of life (1). In a recent publication in Science Advances, Majmundar et al identified recessive mutations in Nitric Oxide Synthase 1 Adaptor Protein (NOS1AP) as another genetic cause of early-onset SRNS (2).
      Citation: Kidney International (2021)
      PubDate: 2021-03-05
      DOI: 10.1016/j.kint.2021.02.036
  • Acute kidney injury in pediatric patients hospitalized with acute COVID-19
           and Multisystem Inflammatory Syndrome in Children associated with COVID-19
    • Authors: Abby Basalely; Shari Gurusinghe, James Schneider, Sareen S. Shah, Linda B. Siegel, Gabrielle Pollack, Pamela Singer, Laura J. Castellanos-Reyes, Steven Fishbane, Kenar D. Jhaveri, Elizabeth Mitchell, Kumail Merchant, Christine Capone, Ashley M. Gefen, Julie Steinberg, Christine B. Sethna
      Abstract: This study describes the incidence, associated clinical characteristics and outcomes of acute kidney injury in a pediatric cohort with COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C). We performed a retrospective study of patients 18 years of age and under admitted to four New York hospitals in the Northwell Health System interned during the height of the COVID-19 pandemic, between March 9 and August 13, 2020. Acute kidney injury was defined and staged according to Kidney Disease: Improving Global Outcomes criteria.
      Citation: Kidney International (2021)
      PubDate: 2021-03-03
      DOI: 10.1016/j.kint.2021.02.026
  • Annexin A1 alleviates kidney injury by promoting the resolution of
           inflammation in diabetic nephropathy
    • Authors: Liang Wu; Changjie Liu, Dong-Yuan Chang, Rui Zhan, Jing Sun, Shi-He Cui, Sean Eddy, Viji Nair, Emily Tanner, Frank C. Brosius, Helen C. Looker, Robert G. Nelson, Matthias Kretzler, Jian-Cheng Wang, Ming Xu, Wenjun Ju, Ming-Hui Zhao, Min Chen, Lemin Zheng
      Abstract: Since failed resolution of inflammation is a major contributor to the progression of diabetic nephropathy, identifying endogenously generated molecules that promote the physiological resolution of inflammation may be a promising therapeutic approach for this disease. Annexin A1 (ANXA1), as an endogenous mediator, plays an important role in resolving inflammation. Whether ANXA1 could affect established diabetic nephropathy through modulating inflammatory states remains largely unknown. In the current study, we found that in patients with diabetic nephropathy, the levels of ANXA1 were upregulated in kidneys, and correlated with kidney function as well as kidney outcomes.
      Citation: Kidney International (2021)
      PubDate: 2021-03-03
      DOI: 10.1016/j.kint.2021.02.025
  • Calpastatin prevents Angiotensin II-mediated podocyte injury through
           maintenance of autophagy
    • Authors: Imane Bensaada; Blaise Robin, Joëlle Perez, Yann Salemkour, Anna Chipont, Marine Camus, Mathilde Lemoine, Lea Guyonnet, Hélène Lazareth, Emmanuel Letavernier, Carole Hénique, Pierre-Louis Tharaux, Olivia Lenoir
      Abstract: The strong predictive value of proteinuria in chronic glomerulopathies is firmly established as well as the pathogenic role of angiotensin II promoting progression of glomerular disease with an altered glomerular filtration barrier, podocyte injury and scarring of glomeruli. Here we found that chronic angiotensin II-induced hypertension inhibited autophagy flux in mouse glomeruli. Deletion of Atg5 (a gene encoding a protein involved autophagy) specifically in the podocyte resulted in accelerated angiotensin II-induced podocytopathy, accentuated albuminuria and glomerulosclerosis.
      Citation: Kidney International (2021)
      PubDate: 2021-03-03
      DOI: 10.1016/j.kint.2021.02.024
  • A novel claudin-10 mutation with a unique mechanism in two unrelated
           families with HELIX syndrome
    • Authors: Ali S. Alzahrani; Maged Hussein, Meshael Alswailem, Ahmad Mouna, Lina Albalawi, Yosra Moria, Mai Abdel Jabbar, Yufei Shi, Dorothee Günzel, Majed Dasouki
      Abstract: HELIX syndrome, characterized by hypohidrosis, electrolyte imbalance, lacrimal gland dysfunction, ichthyosis, and xerostomia due to claudin-10 (CLDN10) mutations was recognized in 2017. Here we describe two unrelated Saudi families with this syndrome due to a novel CLDN10 mutation with a unique mechanism of CLDN10 inactivation. The two consanguineous families include 12 affected individuals (three siblings in family 1 and nine members in family 2). They presented with hypokalemia and the above mentioned features of HELIX syndrome.
      Citation: Kidney International (2021)
      PubDate: 2021-03-03
      DOI: 10.1016/j.kint.2021.02.023
  • Risk factors, histopathological features and graft outcome of transplant
           glomerulopathy in the absence of donor-specific HLA antibodies.
    • Authors: Aleksandar Senev; Elisabet Van Loon, Evelyne Lerut, Jasper Callemeyn, Maarten Coemans, Vicky Van Sandt, Dirk Kuypers, Marie-Paule Emonds, Maarten Naesens
      Abstract: Transplant glomerulopathy is established as a hallmark of chronic antibody-mediated rejection in kidney transplant patients with donor-specific HLA antibodies (HLA-DSA). The clinical importance of transplant glomerulopathy in the absence of HLA-DSA is not well established. To help define this, 954 patients (encompassing 3744 biopsies) who underwent kidney transplantation 2004-2013 were studied with retrospective high-resolution HLA genotyping of both donors and recipients. The risk factors, histopathological appearance and prognosis of cases with transplant glomerulopathy in the absence of HLA-DSA were compared to those cases with HLA-DSA, and the impact of the PIRCHE-II score and eplet mismatches on development of transplant glomerulopathy evaluated.
      Citation: Kidney International (2021)
      PubDate: 2021-03-03
      DOI: 10.1016/j.kint.2021.01.029
  • Enough is enough: Targeted eculizumab withdrawal in atypical haemolytic
           uremic syndrome
    • Authors: R.N. Bouwmeester; N.C.A.J. van de Kar, J.F.M. Wetzels
      Abstract: The introduction of the complement-C5 inhibitor eculizumab has greatly benefitted patients with atypical hemolytic uremic syndrome (aHUS). Initially, eculizumab was proposed as life-long therapy, a societal burden because of its very high costs. Based on limited data, restrictive treatment strategies have been proposed with therapeutic drug monitoring, eculizumab tapering, or early withdrawal.(1) However, the PROS and CONS of such strategies have not been defined. A recent study by Fakhouri and colleagues published in Blood sought to address the feasibility of eculizumab withdrawal in patients with aHUS.(2)
      Citation: Kidney International (2021)
      PubDate: 2021-03-02
      DOI: 10.1016/j.kint.2021.02.033
  • PIEZO2, a mechanosensor in the urinary bladder.
    • Authors: Philippe Gailly; Olivier Devuyst
      Abstract: The functions of the lower urinary tract to store and eliminate urine are regulated by complex neural pathways that coordinate the activity of the smooth and striated muscles of the bladder, urethra, and urethral sphincters.1 Besides control by the central nervous system, micturition reflexes are triggered by bladder filling that stretches the bladder wall and by urine flow in the urethra that triggers a urethra-to-bladder reflex facilitating bladder contraction and emptying. Both the urothelium and the mechanically sensitive afferents from the dorsal root ganglia are involved in stretch and pressure detection.
      Citation: Kidney International (2021)
      PubDate: 2021-03-02
      DOI: 10.1016/j.kint.2021.02.021
  • Removing Race from GFR Estimates: Balancing Potential Benefits and
           Unintended Consequences
    • Authors: Anika Lucas; Christina Wyatt, Lesley A. Inker
      Abstract: In recent years, there has been growing concern about the use of race, a social construct, in medical decision-making (1-4). Calls for change reached a new volume in 2020, sparked by widespread protests against systemic racism in the United States (US). Recognizing significant racial disparities in kidney health in the US and worldwide, questions have been raised about the inclusion of race in equations to estimate creatinine-based GFR (eGFRCr)(2).
      Citation: Kidney International (2021)
      PubDate: 2021-02-26
      DOI: 10.1016/j.kint.2021.02.017
  • Decreased monocyte calcium sensing receptor expression in patients with
           chronic kidney disease is associated with impaired monocyte ability to
           reduce vascular calcification.
    • Authors: Thibaut Objois; Aurélien Mary, Michel Brazier, Y. Bennis, Cédric Boudot, Gaëlle Lenglet, Julien Paccou, Jean-Marc Bugnicourt, Gabriel Choukroun, Tilman B. Drueke, Ziad A. Massy, Saïd Kamel, Isabelle Six, Romuald Mentaverri R
      Abstract: In chronic kidney disease (CKD), calcium-sensing receptor (CaSR) expression and function have been extensively studied in parathyroid tissue and vascular tissues. To examine whether similar changes occurred in other tissues, we measured total and surface CaSR expression in monocytes of patients with various stages of CKD and healthy volunteers respectively in cross-sectional studies. We further explored in vitro the impact of uremic serum on CaSR expression in monocytes (U937 and THP-1 cell lines), and whether human peripheral blood mononuclear cells or U937 and THP-1 monocytes might modify vascular calcium deposition in rat carotid arteries in vitro.
      Citation: Kidney International (2021)
      PubDate: 2021-02-26
      DOI: 10.1016/j.kint.2021.01.026
  • Presence of a survival benefit of HLA-incompatible living donor kidney
           transplantation compared to waiting or HLA-compatible deceased donor
           kidney transplantation with a long waiting time.
    • Authors: Tai Yeon Koo; Ju Han Lee, Sang-Il Min, Yonggu Lee, Myung Soo Kim, Jongwon Ha, Soon Il Kim, Curie Ahn, Yu Seun Kim, Jayoun Kim, Kyu Ha Huh, Jaeseok Yang
      Abstract: HLA-incompatible living donor kidney transplantation (LDKT) is one of efforts to increase kidney transplantation opportunity for sensitized patients with kidney failure. However, there are conflicting reports for outcomes of HLA-incompatible kidney transplantation compared to patients who wait for HLA-compatible deceased donor kidney transplantation (DDKT) in the United States and United Kingdom. Waiting for an HLA-compatible DDKT is relatively disadvantageous in Korea, because the average waiting time is more than five years.
      Citation: Kidney International (2021)
      PubDate: 2021-02-25
      DOI: 10.1016/j.kint.2021.01.027
  • Searching for the origin of the myofibroblast one cell at a time
    • Authors: Agnes B. Fogo
      Abstract: Chronic kidney disease (CKD), regardless of the initial injury, is often characterized by relentless progression with ultimate development of tubular atrophy, interstitial fibrosis, and glomerulosclerosis. The extent of tubulointerstitial fibrosis is the morphologic parameter most closely associated with decreased glomerular filtration rate (1). Interstitial fibrosis and tubular atrophy (IF/TA) almost invariably develop in parallel and increased IF/TA is a morphologic indicator of poor prognosis across the full spectrum of kidney diseases.
      Citation: Kidney International (2021)
      PubDate: 2021-02-25
      DOI: 10.1016/j.kint.2021.02.016
  • Hyperphosphatemia in chronic kidney disease exacerbates atherosclerosis
           via a mannosidases-mediated complex-type conversion of SCAP N-glycans
    • Authors: Chao Zhou; Quan He, Hua Gan, Tingting Zeng, Qiao Liu, John F. Moorhead, Zac Varghese, Nan Ouyang, Xiong Z. Ruan
      Abstract: Blood phosphate levels are linked to atherosclerotic cardiovascular disease in patients with chronic kidney disease (CKD), but the molecular mechanisms remain unclear. Emerging studies indicate an involvement of hyperphosphatemia in CKD accelerated atherogenesis through disturbed cholesterol homeostasis. Here, we investigated a potential atherogenic role of high phosphate concentrations acting through aberrant activation of sterol regulatory element-binding protein (SREBP) and cleavage-activating protein (SCAP)-SREBP2 signaling in patients with CKD, hyperphosphatemic apolipoprotein E (ApoE) knockout mice, and cultured vascular smooth muscle cells.
      Citation: Kidney International (2021)
      PubDate: 2021-02-22
      DOI: 10.1016/j.kint.2021.01.016
  • Proteinuria converts hepatic heparan sulfate to an effective proprotein
           convertase subtilisin kexin type 9 enzyme binding partner
    • Authors: Pragyi Shrestha; Saleh Yazdani, Romain R. Vivès, Rana El Masri, Wendy Dam, Bart van de Sluis, Jacob van den Born
      Abstract: Hepatic uptake of triglyceride-rich remnant lipoproteins is mediated by the low-density lipoprotein receptor, a low-density lipoprotein receptor related protein and the heparan sulfate proteoglycan, syndecan-1. Heparan sulfate proteoglycan also mediates low-density lipoprotein receptor degradation by a regulator of cholesterol homeostasis, proprotein convertase subtilisin kexin type 9 (PCSK9), thereby hampering triglyceride-rich remnant lipoproteins uptake. In this study, we investigated the effects of proteinuria on PCSK9, hepatic heparan sulfate proteoglycan and plasma triglyceride-rich remnant lipoproteins.
      Citation: Kidney International (2021)
      PubDate: 2021-02-17
      DOI: 10.1016/j.kint.2021.01.023
  • Making human collecting ducts and modelling disease in the laboratory
    • Authors: Adrian S. Woolf
      Abstract: Human pluripotent stem cells (hPSCs) are derived from early embryos (embryonic SCs) or made by regressing mature tissues (induced PSCs). Theoretically, such cells have the potential to form all tissue types. Reasons to generate kidney tissues from hPSCs include: understanding normal kidney development; modeling kidney disorders; and making kidney cells for regenerative medicine therapies.1
      Citation: Kidney International (2021)
      PubDate: 2021-02-16
      DOI: 10.1016/j.kint.2021.02.012
  • A multicenter blinded preclinical randomized controlled trial on Jak1/2
           inhibition in MRL/MpJ-Faslpr mice with proliferative lupus nephritis
           predicts low effect size.
    • Authors: Yutian Lei; Bettina Sehnert, Reinhard E. Voll, Conxita Jacobs-Cachá, Maria Jose Soler, Maria D. Sanchez-Niño, Alberto Ortiz, Roman D. Bülow, Peter Boor, Hans-Joachim Anders
      Abstract: Data reproducibility and single-center bias are concerns in preclinical research and compromise translation from animal to human. Multicenter preclinical randomized controlled trials (pRCT) may reduce the gap between experimental studies and RCT and improve the predictability of results, for example Jak1/2 inhibition in lupus nephritis. To evaluate this, we conducted the first pRCT in the kidney domain at two Spanish and two German academic sites. Eligible MRL/MpJ-Faslpr mice (female, age13-14 weeks, stress scores of less than two and no visible tumor or signs of infection) were equally randomized to either oral treatment with the Jak1/2 inhibitor baricitinib or vehicle for four weeks.
      Citation: Kidney International (2021)
      PubDate: 2021-02-16
      DOI: 10.1016/j.kint.2021.01.024
  • The time of onset of intradialytic hypotension during a hemodialysis
           session associates with clinical parameters and mortality.
    • Authors: David F. Keane; Jochen G. Raimann, Hanjie Zhang, Joanna Willetts, M.S. Stephan Thijssen, Peter Kotanko
      Abstract: Intradialytic hypotension (IDH) is a common complication of hemodialysis, but there is no data about the time of onset during treatment. Here we describe the incidence of IDH throughout hemodialysis and associations of time of hypotension with clinical parameters and survival by analyzing data from 21 dialysis clinics in the United States to include 785682 treatments from 4348 patients. IDH was defined as a systolic blood pressure of 90 mmHg or under while IDH incidence was calculated in 30-minute intervals throughout the hemodialysis session.
      Citation: Kidney International (2021)
      PubDate: 2021-02-16
      DOI: 10.1016/j.kint.2021.01.018
  • AI Applications in Renal Pathology
    • Authors: Yuankai Huo; Ruining Deng, Quan Liu, Agnes B. Fogo, Haichun Yang
      Abstract: The explosive growth of artificial intelligence (AI) technologies, especially deep learning methods, has been translated at revolutionary speed to efforts in AI-assisted healthcare. New applications of AI to renal pathology have recently become available, driven by the successful AI deployments in digital pathology. However, synergetic developments of renal pathology and AI require close interdisciplinary collaborations between computer scientists and renal pathologists. Computer scientists should understand that not every AI innovation is translatable to renal pathology, while renal pathologists should capture high-level principles of the relevant AI technologies.
      Citation: Kidney International (2021)
      PubDate: 2021-02-10
      DOI: 10.1016/j.kint.2021.01.015
  • Whole exome sequencing of large populations: identification of loss of
           function alleles and implications for inherited kidney diseases
    • Authors: Robert Geraghty; Eric Olinger, John A. Sayer
      Abstract: Technological advances in next-generation DNA sequencing now allow fast and cost-effective sequencing of the ‘exome’, defined as all the exons in the genome. Such is the rapidity and accessibility of this technique that whole exome sequencing (WES) is becoming a first-line diagnostic tool for the investigation of many diseases, including cancers, metabolic disorders, and childhood neurodevelopmental disorders.
      Citation: Kidney International (2021)
      PubDate: 2021-02-04
      DOI: 10.1016/j.kint.2020.12.036
    • Authors: E.M.C. D’Agata; I.W. Apata, S. Booth, J.M. Boyce, K. Deaver, N. Gualandi, A. Neu, D. Nguyen, S. Novosad, P.M. Palevsky, D. Rodgers, the Nephrologist Transforming Dialysis Safety Committee
      First page: 1045
      Abstract: Clostridioides difficile infections (CDI) cause substantial morbidity and mortality. Patients on maintenance hemodialysis (MHD) are 2-2.5 times more likely to develop CDI with mortality rates 2-fold higher than the general population. Hospitalizations due to CDI among the MHD population are high and the frequency of antibiotic exposures and hospitalizations may contribute to CDI risk. In this report, a panel of experts in clinical nephrology, infectious diseases, and infection prevention provide guidance, based on expert opinion and published literature, aimed at preventing the spread of CDI in outpatient hemodialysis facilities.
      Citation: Kidney International (2021)
      PubDate: 2021-03-02
      DOI: 10.1016/j.kint.2021.02.028
  • Uromodulin fights UTI with sugars
    • Authors: Andrew Beenken; Qais Al-Awqati
      First page: 1057
      Abstract: Modification of host receptor proteins with sugars, or glycosylation, is essential for the binding of many pathogens. For instance, Group B streptococcus, Helicobacter pylori, and uropathogenic Type 1 fimbriated Escherichia coli (UPEC), among others, all bind to sugars present on the membrane proteins of epithelial cells. In a recent study published in Science, Weiss et al. have shown that a specific glycosylation on uromodulin is required for it to bind UPEC and prevent colonization of bladder epithelia.
      Citation: Kidney International (2021)
      PubDate: 2021-02-04
      DOI: 10.1016/j.kint.2020.12.035
  • From confusion to clarity: RAS blockade in patients hospitalized with
    • Authors: Raymond Geherty; Matthew A. Sparks
      First page: 1059
      Abstract: The public, scientific, and medical community continues to face unprecedented challenges in dealing with all aspects of the coronavirus disease 2019 (COVID-19) pandemic. Intense debate and research continue to focus on determining why some individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, are asymptomatic or mildly symptomatic, whereas others manifest severe disease, which is often fatal. It was quickly recognized that SARS-CoV-2 uses the angiotensin-converting enzyme-2 (ACE2) protein, a key component of the renin-angiotensin system (RAS), to enter host cells.
      Citation: Kidney International (2021)
      PubDate: 2021-03-19
      DOI: 10.1016/j.kint.2021.02.034
  • Impact of training nephrologists from developing nations and strategies
           for sustaining a training program in its fourth decade
    • Authors: Ikechi G. Okpechi; Allison A. Eddy, Vivekanand Jha, Thomas Jacob, Sophie Dupuis, David C. Harris
      First page: 1073
      Abstract: Physicians from developing countries do not have many opportunities to train in nephrology. The International Society of Nephrology (ISN) Fellowship program was established in 1985 to address workforce shortages1 given that inadequate nephrology workforce2 remains a major hurdle to provision of equitable kidney care globally.3 The density of nephrologists in high-income countries is over 90 times the density in low-income countries while density of nephrology trainees is over 30 times higher in high-income countries than in low-income countries,2 suggesting a disadvantage in care access for populations with low nephrologist densities.
      Citation: Kidney International (2021)
      PubDate: 2021-03-08
      DOI: 10.1016/j.kint.2021.02.029
  • Rho-GTPase Activating Protein myosin MYO9A identified as a novel candidate
           gene for monogenic focal segmental glomerulosclerosis.
    • Authors: Qi Li; Ashima Gulati, Mathieu Lemaire, Timothy Nottoli, Allen Bale, Alda Tufro
      First page: 1102
      Abstract: Focal segmental glomerulosclerosis (FSGS) is a podocytopathy leading to kidney failure, whose molecular cause frequently remains unresolved. Here, we describe a rare MYO9A loss of function nonsense heterozygous mutation (p.Arg701*) as a possible contributor to disease in a sibling pair with familial FSGS/proteinuria. MYO9A variants of uncertain significance were identified by whole exome sequencing in a cohort of 94 biopsy proven patients with FSGS. MYO9A is an unconventional myosin with a Rho-GAP domain that controls epithelial cell junction assembly, crosslinks and bundles actin and deactivates the small GTPase protein encoded by the RHOA gene.
      Citation: Kidney International (2021)
      PubDate: 2021-01-04
      DOI: 10.1016/j.kint.2020.12.022
  • Chlorthalidone with potassium citrate decreases calcium oxalate stones and
           increases bone quality in genetic hypercalciuric stone-forming rats.
    • Authors: Nancy S. Krieger; John Asplin, Ignacio Granja, Luojing Chen, Daiana Spataru, Tong Tong Wu, Marc Grynpas, David A. Bushinsky
      First page: 1118
      Abstract: To study human idiopathic hypercalciuria we developed an animal model, genetic hypercalciuric stone-forming rats, whose pathophysiology parallels that of human idiopathic hypercalciuria. Fed the oxalate precursor, hydroxyproline, every rat in this model develops calcium oxalate stones. Using this rat model, we tested whether chlorthalidone and potassium citrate combined would reduce calcium oxalate stone formation and improve bone quality more than either agent alone. These rats (113 generation) were fed a normal calcium and phosphorus diet with hydroxyproline and divided into four groups: diets plus potassium chloride as control, potassium citrate, chlorthalidone plus potassium chloride, or potassium citrate plus chlorthalidone.
      Citation: Kidney International (2021)
      PubDate: 2021-01-05
      DOI: 10.1016/j.kint.2020.12.023
  • Differential expression of microRNA miR-150-5p in IgA nephropathy as a
           potential mediator and marker of disease progression.
    • Authors: Izabella ZA. Pawluczyk; Athanasios Didangelos, Sean J. Barbour, Lee Er, Jan U. Becker, Roberto Martin, Scott Taylor, Jasraj S. Bhachu, Edward G. Lyons, Robert Jenkins, Donald Fraser, Karen Molyneux, Javier Perales-Patón, Julio Saez-Rodriguez, Jonathan Barratt
      First page: 1127
      Abstract: Understanding why certain patients with IgA nephropathy progress to kidney failure while others maintain normal kidney function remains a major unanswered question. To help answer this, we performed miRnome profiling by next generation sequencing of kidney biopsies in order to identify microRNAs specifically associated with the risk of IgA nephropathy progression. Following sequencing and validation in independent cohorts, four microRNAs (-150-5p, -155-5p, -146b-5p, -135a-5p) were found to be differentially expressed in IgA nephropathy progressors compared to non-progressors, and patients with thin membrane nephropathy, lupus nephritis and membranous nephropathy, and correlated with estimated glomerular filtration rate, proteinuria, and the Oxford MEST-C scores (five histological features that are independent predictors of clinical outcome).
      Citation: Kidney International (2021)
      PubDate: 2021-01-05
      DOI: 10.1016/j.kint.2020.12.028
  • Glomerular filtrate affects the dynamics of podocyte detachment in a model
           of diffuse toxic podocytopathy
    • Authors: Nobuyuki Saga; Kazuo Sakamoto, Taiji Matsusaka, Michio Nagata
      First page: 1149
      Abstract: Podocyte injury and subsequent detachment are hallmarks of progressive glomerulosclerosis. In addition to cell injury, unknown mechanical forces on the injured podocyte may promote detachment. To identify the nature of these mechanical forces, we studied the dynamics of podocyte detachment using sequential ultrastructural geometry analysis by transmission electron microscopy in NEP25, a mouse model of podocytopathy induced by anti-Tac(Fv)-PE38 (LMB2), a fusion protein attached to Pseudomonas exotoxin A, targeting CD25 on podocytes.
      Citation: Kidney International (2021)
      PubDate: 2021-02-11
      DOI: 10.1016/j.kint.2020.12.034
  • Non-oxidized parathyroid hormone (PTH) measured by current method is not
           superior to total PTH in assessing bone turnover in chronic kidney
    • Authors: Stan R. Ursem; Annemieke C. Heijboer, Patrick C. D’Haese, Geert J. Behets, Etienne Cavalier, Marc G. Vervloet, Pieter Evenepoel
      First page: 1173
      Abstract: Parathyroid hormone (PTH) is a key regulator of bone turnover but can be oxidized in vivo, which impairs biological activity. Variable PTH oxidation may account for the rather poor correlation of PTH with indices of bone turnover in chronic kidney disease. Here, we tested whether non-oxidized PTH is superior to total PTH as a marker of bone turnover in 31 patients with kidney failure included from an ongoing prospective observational bone biopsy study and selected to cover the whole spectrum of bone turnover.
      Citation: Kidney International (2021)
      PubDate: 2021-01-07
      DOI: 10.1016/j.kint.2020.12.024
  • GBM nephritis - Crescentic renal inflammation and immunosuppressive
           intervention in the time of the SARS-CoV-2 pandemic
    • Authors: Silke R. Brix; Rachel B. Jones, David R.W. Jayne
      First page: 1234
      Abstract: the diagnosis and management of autoimmune disorders is challenging in the current pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we describe the case of a patient with anti-glomerular-basement-membrane (GBM) disease complicated by a SARS-CoV-2 infection to highlight the importance of appropriate immunosuppression and individualized care in respect of these two disease processes.
      Citation: Kidney International (2021)
      PubDate: 2021-02-10
      DOI: 10.1016/j.kint.2021.02.004
  • Kidney Disorders as Serious Adverse Drug Reactions of Remdesivir in
           Covid-19: A Retrospective Case-Non case Study
    • Authors: Laurent Chouchana; Laure-Hélène Preta, Mylène Tisseyre, Benjamin Terrier, Jean-Marc Treluyer, François Montastruc
      First page: 1235
      Abstract: Remdesivir is a novel adenosine-like nucleotide analogue, representing the first drug approved for coronavirus disease 2019 (Covid-19), albeit an uncertain clinical relevance. In clinical trials and case series, acute kidney injury (AKI), including renal replacement, have been frequently reported.1,2 Although causality is debatable, kidney injuries especially proximal tubular epithelial cell necrosis have also been observed in animal studies during remdesivir development.
      Citation: Kidney International (2021)
      PubDate: 2021-02-25
      DOI: 10.1016/j.kint.2021.02.015
  • Zero healthcare-associated respiratory viral infections: impact of
           enhanced infection prevention on a renal unit during the COVID-19 pandemic
    • Authors: Liang En Wee; Chieh Suai Tan, Edwin Philip Conceicao, Indumathi Venkatachalam
      First page: 1236
      Abstract: We read with interest the study by Thaunat et al. that identified significant excess mortality attributed to COVID-19 amongst dialysis patients.1 Indeed, the COVID-19 pandemic has provided the impetus for the introduction of strategies to optimise protection of hemodialysis patients from SARS-CoV-2.2 Outside the pandemic setting, however, patients with chronic-kidney-disease have significantly higher risk of nosocomial acquisition of other common respiratory-viral-infections (RVIs), with increased mortality and length-of-stay.
      Citation: Kidney International (2021)
      PubDate: 2021-03-02
      DOI: 10.1016/j.kint.2021.02.020
  • Answering the call to action: rapid implementation of an in-center
           hemodialysis severe acute respiratory syndrome coronavirus vaccination
    • Authors: Sarah Gleeson; Paul Martin, Rachna Bedi, Kathleen Lynch, Michelle Willicombe, Liz Lightstone
      First page: 1238
      Abstract: The coronavirus pandemic resulted in devastatingly high rates of infection and mortality (up to 20% and 32%, respectively) for patients receiving in-center hemodialysis (ICHD).1 The arrival of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines was anxiously awaited. Large trials reported vaccine efficacy of 62% to 95%.2,3 Data from other vaccines suggested benefit in kidney patients, despite attenuated immune responses.4 Given the devastating toll of coronavirus disease (COVID), and the kidney community’s call to action,1 we advocated for urgent provision of SARS-CoV-2 vaccines for patients receiving ICHD.
      Citation: Kidney International (2021)
      PubDate: 2021-03-22
      DOI: 10.1016/j.kint.2021.03.007
  • A multi-center study on safety and efficacy of immune checkpoint
           inhibitors in cancer patients with kidney transplant.
    • Authors: Naoka Murakami; Patrick Mulvaney, Melissa Danesh, Ala Abudayyeh, Adi Diab, Noha Abdel-Wahab, Maen Abdelrahim, Pascale Khairallah, Shayan Shirazian, Aleksandra Kukla, Itunu O. Owoyemi, Tarek Alhamad, Samir Husami, Madhav Menon, Andrew Santeusanio, Christopher Blosser, Sandra Carias Zuniga, Maria Jose Soler, Francesc Moreso, Zain Mithani, David Ortiz-Melo, Edgar A. Jaimes, Victoria Gutgarts, Erik Lum, Gabriel M. Danovitch, Francesca Cardarelli, Reed E. Drews, Claude Bassil, Jennifer L. Swank, Scott Westphal, Roslyn B. Mannon, Keisuke Shirai, Abhijat Kitchlu, Song Ong, Shana M. Machado, Suraj S. Mothi, Patrick A. Ott, Osama Rahma, F. Stephen Hodi, Meghan E. Sise, Shruti Gupta, David E. Leaf, Craig E. Devoe, Rimda Wanchoo, Vinay V. Nair, Chrysalyne D. Schmults, Glenn J. Hanna, Ben Sprangers, Leonardo V. Riella, Kenar D. Jhaveri, Immune Checkpoint Inhibitors in Solid Organ Transplant Consortium
      Abstract: Immune checkpoint inhibitors (ICIs) are widely used for various malignancies. However, their safety and efficacy in patients with a kidney transplant have not been defined. To delineate this, we conducted a multicenter retrospective study of 69 patients with a kidney transplant receiving ICIs between January 2010 and May 2020. For safety, we assessed the incidence, timing, and risk factors of acute graft rejection. For efficacy, objective response rate and overall survival were assessed in cutaneous squamous cell carcinoma and melanoma, the most common cancers in our cohort, and compared with stage-matched 23 patients with squamous cell carcinoma and 14 with melanoma with a kidney transplant not receiving ICIs.
      Citation: Kidney International (2020)
      PubDate: 2020-12-23
      DOI: 10.1016/j.kint.2020.12.015
  • Supplemented ERA-EDTA Registry data evaluated the frequency of dialysis,
           kidney transplantation and comprehensive conservative management for
           patients with kidney failure in Europe.
    • Authors: Vianda S. Stel; Rianne W. de Jong, Anneke Kramer, Anton M. Andrusev, José M. Baltar, Myftar Barbullushi, Samira Bell, Pablo Castro de la Nuez, Harijs Cernevskis, Cécile Couchoud, Johan De Meester, Bjørn O. Eriksen, Lilliana Garneata, Eliezer Golan, Jaakko Helve, Marc H. Hemmelder, Kristine Hommel, Kyriakos Ioannou, Faiçal Jarraya, Nino Kantaria, Julia Kerschbaum, Kirill S. Komissarov, Ángela Magaz, Lucile Mercadal, Mai Ots-Rosenberg, Runolfur Palsson, Axel Rahmel, Helena Rydell, Manuela Savino, Nurhan Seyahi, Maria F. Slon Roblero, Olivera Stojceva-Taneva, Arjan Van der Tol, Evgueniy S. Vazelov, Edita Ziginskiene, Oscar Zurriaga, Raymond C. Vanholder, Ziad A. Massy, Kitty J. Jager
      Abstract: The aims of this study were to determine the frequency of dialysis and kidney transplantation and to estimate the regularity of comprehensive conservative management (CCM) for patients with kidney failure in Europe. This study uses data from the ERA-EDTA Registry. Additionally, our study included supplemental data from Armenia, Germany, Hungary, Ireland, Kosovo, Luxembourg, Malta, Moldova, Montenegro, Slovenia and additional data from Israel, Italy, Slovakia using other information sources. Through an online survey, responding nephrologists estimated the frequency of CCM (i.e.
      Citation: Kidney International (2020)
      PubDate: 2020-12-21
      DOI: 10.1016/j.kint.2020.12.010
  • Development and external validation combining existing models and recent
           data into an up-to-date prediction model for evaluating kidneys from older
           deceased donors for transplantation.
    • Authors: Chava L. Ramspek; Mostafa El Moumni, Eelaha Wali, Martin B.A. Heemskerk, Robert A. Pol, Meindert J. Crop, Nichon E. Jansen, Andries Hoitsma, Friedo W. Dekker, M. van Diepen, Cyril Moers
      Abstract: With a rising demand for kidney transplantation, reliable pre-transplant assessment of organ quality becomes top priority. In clinical practice, physicians are regularly in doubt whether suboptimal kidney offers from older donors should be accepted. Here, we externally validate existing prediction models in a European population of older deceased donors, and subsequently developed and externally validated an adverse outcome prediction tool. Recipients of kidney grafts from deceased donors 50 years of age and older were included from the Netherlands Organ Transplant Registry (NOTR) and United States organ transplant registry from 2006-2018.
      Citation: Kidney International (2020)
      PubDate: 2020-12-16
      DOI: 10.1016/j.kint.2020.11.016
  • Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating
           in the Middle Ages is predominant in Central/East Europe and causes kidney
           failure in midlife.
    • Authors: Aleksandra M. Żurowska; Olga Bielska, Patrycja Daca-Roszak, Maciej Jankowski, Maria Szczepańska, Danuta Roszkowska-Bjanid, Elżbieta Kuźma-Mroczkowska, Małgorzata Pańczyk-Tomaszewska, Anna Moczulska, Dorota Drożdż, Despina Hadjipanagi, Constantinos Deltas, Danuta Ostalska-Nowicka, Alina Rabiega, Janina Taraszkiewicz, Katarzyna Taranta-Janusz, Anna Wieczorkiewicz-Plaza, Katarzyna Jobs, Judyta Mews, Kinga Musiał, Anna Jakubowska, Hanna Nosek, Anna E. Jander, Constantina Koutsofti, Anna Stanisławska-Sachadyn, Dominka Kuleszo, Ewa Ziętkiewicz, Beata S. Lipska-Ziętkiewicz
      Abstract: A study of 269 children enrolled into a National Registry for children with persistent glomerular hematuria identified 131 individuals with genetically confirmed X-linked Alport Syndrome. A single variant c.1871G>A p.Gly624Asp (G624D) in COL4A5 was predominant and accounted for 39% of X-linked Alport Syndrome in unrelated Polish families (44 of 113). To evaluate its origins, the genetic variation in a 2.79 Mb segment encompassing the COL4A5 locus on chromosome X was assessed. All G624D alleles were found on the same rare haplotype background, indicating a founder effect dating back to the 12-13th century.
      Citation: Kidney International (2020)
      PubDate: 2020-12-10
  • The long-acting C5 inhibitor, ravulizumab, is effective and safe in
           pediatric patients with atypical hemolytic uremic syndrome naïve to
           complement inhibitor treatment
    • Authors: Gema Ariceta; Bradley P. Dixon, Seong Heon Kim, Gaurav Kapur, Teri Mauch, Stephan Ortiz, Marc Vallee, Andrew E. Denker, Hee Gyung Kang, Larry A. Greenbaum
      Abstract: Ravulizumab, a long-acting complement C5 inhibitor engineered from eculizumab, allows extending maintenance dosing from every 2–3 weeks to every 4–8 weeks depending on bodyweight. Here, we evaluated the efficacy and safety of ravulizumab in complement inhibitor-naïve children (under 18 years) with atypical hemolytic uremic syndrome. In this phase III, single-arm trial, ravulizumab was administered every eight weeks in patients 20 kg and over, and four weeks in patients under 20 kg. The primary endpoint was a complete thrombotic microangiopathy response (normalization of platelet count and lactate dehydrogenase, and a 25% or more improvement in serum creatinine) through 26 weeks.
      Citation: Kidney International (2020)
      PubDate: 2020-12-08
  • Updating the International IgA Nephropathy Prediction Tool for use in
    • Authors: Sean J. Barbour; Rosanna Coppo, Lee Er, Maria Luisa Russo, Zhi-Hong Liu, Jie Ding, Ritsuko Katafuchi, Norishige Yoshikawa, Hong Xu, Shoji Kagami, Yukio Yuzawa, Francesco Emma, Alexandra Cambier, Licia Peruzzi, Robert J. Wyatt, Daniel C. Cattran, International IgA Nephropathy Network
      Abstract: Although IgA nephropathy (IgAN) is a common cause of glomerulonephritis in children, the absence of a method to predict disease progression limits personalized risk-based treatment decisions. The adult International IgAN Prediction Tool comprises two validated Cox survival models that predict a 50% decline in estimated glomerular filtration rate (eGFR) or end stage kidney disease (ESKD) using clinical risk factors and Oxford MEST histology scores. Here, we updated the Prediction Tool for use in children using a multiethnic international cohort of 1,060 children with IgAN followed into adulthood.
      Citation: Kidney International (2020)
      PubDate: 2020-11-17
  • Changes in cancer incidence and outcomes among kidney transplant
           recipients in the United States over a thirty-year period.
    • Authors: Christopher D. Blosser; Gregory Haber, Eric A. Engels
      Abstract: Recipients of kidney transplants have elevated cancer risk compared with the general population. Improvements over time in transplant care and cancer treatment may have affected incidence and outcomes of cancer among recipients of kidney transplant. To evaluate this, we used linked United States transplant and cancer registry data to study 101,014 adult recipients of kidney transplants over three decades (1987-1996, 1997-2006, 2007-2016). Poisson regression was used to assess trends in incidence for cancer overall and seven common cancers.
      Citation: Kidney International (2020)
      PubDate: 2020-11-04
  • Clinical and immunological follow-up of very long-term kidney transplant
    • Authors: Amaury Dujardin; Mélanie Chesneau, Florian Dubois, Richard Danger, Linh Bui, Clarisse Kerleau, Pierrick Guérif, Sophie Brouard, Jacques Dantal
      Abstract: Operationally tolerant kidney transplant recipients harbor an immunological signature, associated with low rejection risk, and focused on B lymphocytes. Here, we investigated whether patients with long-term transplantation and still on immunosuppressive therapy would present such a signature of low immunological rejection risk, compared to more recently transplanted patients. Of 114 kidney transplant recipients enrolled, 38 with more than 25 years of graft survival and stable graft function under calcineurin inhibitors, were matched with two different groups of transplanted patients (10-15 and 5-7 years after transplantation).
      Citation: Kidney International (2020)
      PubDate: 2020-10-30
      DOI: 10.1016/j.kint.2020.09.036
  • Neural cell adhesion molecule 1 is a novel autoantigen in membranous lupus
    • Authors: Tiffany Caza; Samar Hassen, Michael Kuperman, Shree Sharma, Zeljko Dvanajscak, John Arthur, Rick Edmondson, Aaron Storey, Christian Herzog, Daniel Kenan, Christopher Larsen
      Abstract: Membranous lupus nephritis is a frequent cause of nephrotic syndrome in patients with systemic lupus erythematosus. It has been shown in phospholipase A2 receptor positive membranous; nephropathy that known antibodies can be detected within sera, determination of the target; autoantigen can have diagnostic significance, inform prognosis, and enable non-invasive; monitoring of disease activity. Here we utilized mass spectrometry for antigen discovery in laser; captured microdissected glomeruli from formalin-fixed paraffin embedded tissue and tissue; protein G immunoprecipitation studies to interrogate immune complexes from frozen kidney; biopsy tissue.
      Citation: Kidney International (2020)
      PubDate: 2020-10-09
      DOI: 10.1016/j.kint.2020.09.016
  • Innate lymphoid cells in kidney diseases
    • Authors: Ruifeng Wang; Yiping Wang, David C.H. Harris, Qi Cao
      First page: 1077
      Abstract: It is well known that innate immune cells, including dendritic cells, macrophages and natural killer cells contribute to pathogenesis and protection in various kidney diseases. The understanding of innate immunity has been advanced recently by the discovery of a new group of innate lymphoid cells (ILCs) including ILC1, ILC2, and ILC3. ILCs lack adaptive antigen receptors, yet can be triggered by various pathogens and rapidly provide an abundant source of immunomodulatory cytokines to exert immediate immune reactions and direct subsequent innate and adaptive immune responses.
      Citation: Kidney International (2020)
      PubDate: 2020-12-29
      DOI: 10.1016/j.kint.2020.11.023
  • Empagliflozin restores chronic kidney disease-induced impairment of
           endothelial regulation of cardiomyocyte relaxation and contraction
    • Authors: Rio P. Juni; Rushd Al-Shama, Diederik W.D. Kuster, Jolanda van der Velden, Henrike M. Hamer, Marc G. Vervloet, Etto C. Eringa, Pieter Koolwijk, Victor W.M. van Hinsbergh
      First page: 1088
      Abstract: Chronic kidney disease (CKD) promotes development of cardiac abnormalities and is highly prevalent in patients with heart failure, particularly in those with preserved ejection fraction. CKD is associated with endothelial dysfunction, however, whether CKD can induce impairment of endothelium-to-cardiomyocyte crosstalk leading to impairment of cardiomyocyte function is not known. The sodium-glucose co-transporter 2 inhibitor, empagliflozin, reduced cardiovascular events in diabetic patients with or without CKD, suggesting its potential as a new treatment for heart failure with preserved ejection fraction.
      Citation: Kidney International (2020)
      PubDate: 2020-12-22
      DOI: 10.1016/j.kint.2020.12.013
  • Upregulation of HLA-F expression by BK polyomavirus infection induces
           immune recognition by KIR3DS1-positive natural killer cells.
    • Authors: Tobias F. Koyro; Emma Kraus, Sebastian Lunemann, Angelique Hölzemer, Sonia Wulf, Johannes Jung, Pia Fittje, Florian Henseling, Christian Körner, Tobias B. Huber, Adam Grundhoff, Thorsten Wiech, Ulf Panzer, Nicole Fischer, Marcus Altfeld
      First page: 1140
      Abstract: BK polyomavirus-associated nephropathy is a common complication after kidney transplantation leading to reduced graft function or loss. The molecular pathogenesis of BK polyomavirus-induced nephropathy is not well understood. A recent study had described a protective effect of the activating natural killer cell receptor KIR3DS1 in BK polyomavirus-associated nephropathy, suggesting a role of NK cells in modulating disease progression. Using an in vitro cell culture model of human BK polyomavirus infection and kidney biopsy samples from patients with BK polyomavirus-associated nephropathy, we observed significantly increased surface expression of the ligand for KIR3DS1, HLA-F, on BK polyomavirus-infected kidney tubular cells.
      Citation: Kidney International (2020)
      PubDate: 2020-12-22
      DOI: 10.1016/j.kint.2020.12.014
  • A case-control study indicates that coagulation imbalance is associated
           with arteriosclerosis and markers of endothelial dysfunction in kidney
    • Authors: Lucie Tran; Bruno Pannier, Patrick Lacolley, Tomas Serrato, Athanase Benetos, Gérard M. London, Yvonnick Bézie, Véronique Regnault
      First page: 1162
      Abstract: Endothelial dysfunction, one of many causes of arterial changes in end-stage kidney disease (kidney failure). is a likely link between early vascular aging and the risk of thrombosis or bleeding in this condition To evaluate this, we compared links between arterial stiffness and endothelial/coagulation factors in 55 patients receiving hemodialysis therapy and 57 age-/sex-matched control individuals. Arterial stiffness was assessed from carotid-femoral pulse wave velocity, and coagulation status from the endogenous thrombin generating potential.
      Citation: Kidney International (2020)
      PubDate: 2020-12-22
      DOI: 10.1016/j.kint.2020.12.011
  • Development and testing of an artificial intelligence tool for predicting
           end stage kidney disease in patients with immunoglobulin A nephropathy.
    • Authors: Francesco Paolo Schena; Vito Walter Anelli, Joseph Trotta, Tommaso Di Noia, Carlo Manno, Giovanni Tripepi, Graziella D’Arrigo, Nicholas C. Chesnaye, Maria Luisa Russo, Maria Stangou, Aikaterini Papagianni, Carmine Zoccali, Vladimir Tesar, Rosanna Coppo
      First page: 1179
      Abstract: We have developed an artificial neural network prediction model for end-stage kidney disease (ESKD) in patients with primary immunoglobulin A nephropathy (IgAN) using a retrospective cohort of 948 patients with IgAN. Our tool is based on a two-step procedure of a classifier model that predicts ESRD, and a regression model that predicts development of ESKD over time. The classifier model showed a performance value of 0.82 (area under the receiver operating characteristic curve) in patients with a follow-up of five years, which improved to 0.89 at the ten-year follow-up.
      Citation: Kidney International (2020)
      PubDate: 2020-09-01
      DOI: 10.1016/j.kint.2020.07.046
  • Time-dependent lymphocyte count after transplantation is associated with
           higher risk of graft failure and death.
    • Authors: Amaury Dujardin; Marine Lorent, Yohann Foucher, Christophe Legendre, Clarisse Kerleau, Sophie Brouard, Magali Giral, DIVAT consortium
      First page: 1189
      Abstract: The transplantation field requires the identification of specific risk factors associated with the level of immunosuppression. Here, our aim was to analyze the association between the number of circulating lymphocytes, monitored routinely by complete blood cell counts during outpatient visits, and patient and graft survival. In total, 2,999 kidney or combined kidney-pancreas recipients transplanted between 2000 and 2016, from two University hospitals, were enrolled. We investigated the etiological relationship between time-dependent lymphocyte count beyond one year after transplantation and patient and graft survival, viral infection and cancer risk using time-dependent multivariate Cox models.
      Citation: Kidney International (2020)
      PubDate: 2020-09-03
      DOI: 10.1016/j.kint.2020.08.010
  • Renin-angiotensin aldosterone inhibitor use at hospital discharge among
           patients with moderate to severe acute kidney injury and its association
           with recurrent acute kidney injury and mortality.
    • Authors: Edward D. Siew; Sharidan K. Parr, Khaled Abdel-Kader, Amy M. Perkins, Robert A. Greevy, Andrew J. Vincz, Jason Denton, Otis D. Wilson, Adriana M. Hung, T. Alp Ikizler, Cassianne Robinson-Cohen, Michael E. Matheny
      First page: 1202
      Abstract: Recurrent episodes of acute kidney injury (AKI) are common among AKI survivors. Renin-angiotensin aldosterone inhibitors (RAASi) are often indicated for these patients but may increase the risk for recurrent AKI. Here, we examined whether RAASi associates with a higher risk for recurrent AKI and mortality among survivors of moderate to severe AKI in a retrospective cohort of Veterans who survived Stage II or III AKI. The primary exposure was RAASi at hospital discharge and the primary endpoint was recurrent AKI within 12 months.
      Citation: Kidney International (2020)
      PubDate: 2020-09-08
      DOI: 10.1016/j.kint.2020.08.022
  • Plasma cadmium is associated with increased risk of long-term kidney graft
    • Authors: Camilo G. Sotomayor; Dion Groothof, Joppe J. Vodegel, Michele F. Eisenga, Tim J. Knobbe, Jan IJmker, Rosa G.M. Lammerts, Martin H. de Borst, Stefan P. Berger, Ilja M. Nolte, Ramón Rodrigo, Riemer H.J.A. Slart, Gerjan J. Navis, Daan J. Touw, Stephan J.L. Bakker
      First page: 1213
      Abstract: The kidney is one of the most sensitive organs to cadmium-induced toxicity, particularly in conditions of long-term oxidative stress. We hypothesized that, in kidney transplant recipients, nephrotoxic exposure to cadmium represents an overlooked hazard for optimal graft function. To test this, we performed a prospective cohort study and included 672 outpatient kidney transplant recipients with a functioning graft of beyond one year. The median plasma cadmium was 58 ng/L. During a median 4.9 years of follow-up, 78 kidney transplant recipients developed graft failure with a significantly different distribution across tertiles of plasma cadmium (13, 26, and 39 events, respectively).
      Citation: Kidney International (2020)
      PubDate: 2020-09-13
      DOI: 10.1016/j.kint.2020.08.027
  • EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an
           indication of efficacy in a Phase 1b randomized cross-over trial in
           hemodialysis patients.
    • Authors: Kathleen M. Hill Gallant; Elizabeth R. Stremke, Laurie Trevino, Ranjani N. Moorthi, Simit Doshi, Meryl E. Wastney, Nozomi Hisada, Jotaro Sato, Yoshitaka Ogita, Naohisa Fujii, Yuya Matsuda, Takei Kake, Sharon M. Moe
      First page: 1225
      Abstract: The treatment of hyperphosphatemia remains challenging in patients receiving hemodialysis. This Phase 1b study assessed safety and efficacy of EOS789, a novel pan-inhibitor of phosphate transport (NaPi-2b, PiT-1, PiT-2) on intestinal phosphate absorption in patients receiving intermittent hemodialysis therapy. Two cross-over, randomized order studies of identical design (ten patients each) compared daily EOS789 50 mg to placebo with meals and daily EOS789 100 mg vs EOS789 100 mg plus 1600 mg sevelamer with meals.
      Citation: Kidney International (2020)
      PubDate: 2020-10-30
      DOI: 10.1016/j.kint.2020.09.035
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762

Your IP address:
Home (Search)
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-